Loma Linda University

TheScholarsRepository@LLU: Digital Archive of Research,
Scholarship & Creative Works
Loma Linda University Electronic Theses, Dissertations & Projects
6-1998

IGF-II Expression in Human Tumor Tissues and Human IGF-II
Ribozyme Action
Zhaodong Xu

Follow this and additional works at: https://scholarsrepository.llu.edu/etd
Part of the Microbiology Commons, and the Molecular Genetics Commons

Recommended Citation
Xu, Zhaodong, "IGF-II Expression in Human Tumor Tissues and Human IGF-II Ribozyme Action" (1998).
Loma Linda University Electronic Theses, Dissertations & Projects. 1649.
https://scholarsrepository.llu.edu/etd/1649

This Dissertation is brought to you for free and open access by TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. It has been accepted for inclusion in Loma Linda University Electronic
Theses, Dissertations & Projects by an authorized administrator of TheScholarsRepository@LLU: Digital Archive of
Research, Scholarship & Creative Works. For more information, please contact scholarsrepository@llu.edu.

BNIVERSITY LIBRARY

SmA LINDA. CALIFORNTA

LOMA LINDA Lns^VERSITY

Graduate School

IGF-II EXPRESSION IN HUMAN TUMOR TISSUES AND HUMAN
IGF-IIRIBOZYME ACTION

Zhaodong Xu

A Dissertation Submitted in partial Fulfillment ofthe Requirements for the Degree of
Doctor ofPhilosophy in Microbiology and Molecular Genetics

June 1998

Each person whose signature appears below certifies that this dissertation in their
opinion is adequate, in scope and quality, as a dissertation for the Degree of Doctor of
Philosophy.

Chairperson

Yoko Fujna-Yamaguchi, Research Professor of Microbiology and Molecular
Genetics and Research Scientist of Molecular Biology, Beckman Research Institute of
City of Hope

Daisy De Leon, Associate Professor ofPhysiology

Keiichi Itakura, Research Professor of Microbiology and Molecular Genetics and
Research Scientist of Molecular Biology, Beckman Research Institute of City of
Hope

ni

James Kettering, Professor of Microbiolo^Jand Molecular Genetics

Aw ///W.'

JohriJ Rossi/Professor of Microbiology and Molecular Genetics and Research
Scientist of Molecular Biology, Beckm^ Research Institute of City of Hope

John Termini, Assistant Research Scientist of Molecular Biology, Beckman Research

Institute of City of Hope.//

ACKNOWLEDGEMENTS

I would like to express sincere thanks to my advisor, Dr. Yoko. Fujita-Yamaguchi, for
her guidance and suggestions during this study. I would also like to thank Dr. John J.
Rossi for his assistance and resourceful advice. I would like to thank Dr. S. Mohan

and Dr. N. S. Lee for their help in this study. I would also like to thank Dr. T. R.
LeBon for his critical reviewing ofthis dissertation. I am grateful also to my
committee members for their expert advice and Loma Linda University Department

of Microbiology and Molecular Genetics for their support in pursuit of this graduate
degree.

TABLE OF CONTENTS

LIST OF FIGURES
LIST OF TABLES ABBREVIATIONS
ABSTRACT

1.

INTRODUCTION

A. IGF System
1. IGFs

(1) IGF-I
(2) IGF-II
2. IGF Receptors
(1) Type I IGF receptor
(2) Type II IGF receptor

3. IGF Binding Proteins(IGFBPs)
(1) IGFBP-1
(2) IGFBP-2
(3) IGFBP-3
(4) IGFBP-4
(5) IGFBP-5
(6) IGFBP-6

B. IGF System and Tumor
(1) Type I and Type II IGF receptor
(2)IGFs expression in tumors
(3) Autocrine /paracrine actions ofIGFs
(4)IGFBPs

(5)IGF system in benign and cancerous prostate tissues(6)Loss ofimprinting in cancer—
C. Ribozyme
1. Discovery of Ribozymes

2. Ribozyme classification
(1) Hammerhead Ribozyme
(2) Hairpin Ribozyme
(3) Hepatitis delta virus ribozyme
(4) Group I Intron
(5) Group II Intron
(6) Ribonuclease P
3. Ribozyme delivery
4. Ribozymes as antineoplastic agents
5. Factors affecting hammerhead ribozyme cleavage in vitro6. Problems underlying the effective use of ribozymes
as therapeutic agents

D. Overview-

E. Goals and Objectives ofthe Project-

11. EXPRESSION OF INSULIN-LIKE GROWTH

FACTOR(IGF-II)IN HUMAN PROSTATE,BREAST,
BLADDER AND PARAGANGLIOMA TUMORS
A. Abstract-

B. Introduction-

C. Materials and MethodsD. Results-

E. Discussion-

F. AcknowledgementsG. ReferencesIll. MATERIALS AND METHODSA. Materials
1.

Cells

2.
3.

Reagents
Molecular Biology Solutions-

4.

Miscellaneous Materials

B. Methods-

Plasmid preparation
(1). Alkali Lysis preparation
(2). Wizard mini-preparation
(3). Qiagen maxi-preparation
Sequencing
Oligonucleotide Probe Labeling and Purification
RNA extraction

Design, construction, and expression ofIGF-II ribozymes(1)Design ofIGF-II ribozymes
(2) Subcloning of a IGF-II substrate
(3) Construction ofIGF-II ribozymes
(4)Preparation ofIGF-II mRNA substrate
by in vitro transcription

(5)In vitro transcription ofIGF-II ribozymes
(6)Ribozyme cleavage assays
6. Kinetic analysis of single- and double-head ribozymes
7. Expression ofIGF-II ribozymes in cancer cell lines
(1) Selection of cell lines
(2)Determination of optimum concentrations
of G4I8 for selection of transformants

(3) Cell culture and transfections
a) Calcium phosphate
b)Electroporation
(4) Expression ofthe hammerhead ribozymes
in cancer cell lines

8. Effect ofIGF-II ribozyme expression on cancer cell lines—
(1) Quantitative analysis of endogenous IGF-II levels
by QC-RTPCR

a). Construct QC-RTPCR internal control plasmid
b). Synthesis of QC-RTPCR internal
control(competitor)RNA
c). Quantitative analysis ofinternal
control(competitor)RNA
d). Analysis ofinternal control vs PCR cycle numbere). Quantitation ofIGF-II abundance
in ribozyme expressing clones
(2). Measurements ofIGF-II protein levels
in PC-3 transfectants.

(3). Effect ofribozyme expression on PC-3 cell growth—
a). MTT Assay
b). Time-lapse microscopy
IV. RESULTS-

A. In vitro IGF-II ribozyme actions
1. Ribozyme cleavage reactions
2. Kinetic analysis on single- and double-ribozymesB. Quantitation ofIGF-II mRNA by QC-RTPCR1. Synthesis of internal control IGF-II
2. Quantitative IGF-II mRNA analysis

C. IGF-II ribozyme action in cancer cells
1. Expression ofIGF-II ribozyme in human prostate
cancer cells under the control ofPol III promoter
(1). Ribozyme expression in PC-3 transfectants
(2). Effect on IGF-II mRNA levels
(3). Effect on cell growth
2. Expression ofIGF-II ribozyme in human prostate
cancer cells under the control ofPol II promoter—

(1). Ribozyme expression in PC-3 transfectants
(2). Effect ofIGF-II ribozyme on IGF-II mRNA levels(3). Effect ofIGF-II ribozyme on IGF-II protein levels(4). Effect ofIGF-II ribozyme on cell growtha). MTT assay

b). Time-lapse microscopy
D. SummaryV. GENERAL DISCUSSION-

A. IGF-II expression in human tumor tissuesB. IGF-II ribozyme actionC. Observation-

D. Mechanisms by which suppression ofIGF-II RNA
and protein affects cancer cell growth
E. Prostate cancer therapyF. ConclusionVI. REFERENCES-

LIST OF FIGURES

Figure
1. Primary structure ofIGF-1 receptor

2. Proposed signaling pathways for IGF-I receptors-

3. Schematic representation of mitogenic stimulation in
normal and transformed cells

4. Structure ofthe hammerhead ribozyme

5. Minimal catalytic cycle of a hammerhead ribozyme

6. Summary ofthe base requirements for a hairpin ribozyme7. The consensus sequence and structure of Group I introns—
8. Model of RNase P substrate-

9. Detection ofIGF-II and IGF-I mRNA in human

prostate cancer cells

10. IGF-II mRNA expression in prostate and breast
cancers as examined by in situ hybridization
11. IGF-II mRNA expression in cancerous and
benign epithelial cells from prostate tissues
12. IGF-II expression in bladder and paraganglioma tumors
13. Western immunoblot analysis ofIGF-II protein
expressed in malignant and normal tissues
14. IGF-II ribozyme sequences

15. Structure of single- and double-IGF-II ribozymes
16. Maps of pTZU6+27 and pcDNA3 ribozymes
\1. In vitro ribozyme cleavage reactions
18. Ribozyme activity against precursor IGF-II RNA
19. Comparison of single- and double-ribozyme kinetics
20. Flow chart of construction of the intemal

control(Competitor) plasmid

21. Intemal control(competitor) titration curve and cycle curve22. Expression ofribozymes under Pol III promoter
in PC-3 transfectants and quantitation of endogenous
IGF-II mRNA levels by quantitative RT-PCR
23. Schematic illustration of QC-RTPCR-

24. Expression of ribozyme under Pol II promoter and
measurements ofIGF-II mRNA and protein
levels in PC-3 transfectants

25. Effect ofribozyme expression on PC-3 cell
growth as measured by MTT assay

LIST OF TABLES

1. Expression ofIGF-II mRNA in benign and malignant
prostate as measured by in situ hybridization
2. Expression ofIGF-II mRNA in breast tumor tissues3. Summary ofIGF-II expression in prostate, breast,
bladder, and paraganglioma tumors as deteeted by
ISH,IHC, and Western Immunoblotting
4. Kinetics of single- and double-ribozymes-

5. Effect ofribozyme expression(pTZU6+27)on PC-3 cell growth—
6. Effect ofribozyme expression(pcDNA3 vector)
on PC-3 cell growth as measured by time-lapse microscopy-

ABBREVIATIONS

Alkaline phosphatase
bovine serum albumin

base pair

cyclic adenosine monophosphate
curies

conditioned medium

diethylpyrocarbonate
dimethyl sulfoxide
human prostate cell
epidermal growth factor
fetal calf serum

follicle stimulating hormone
Genecitin

growth hormone
hematoxylin and eosin
immunohistochemistry
insulin-like growth factor

insulin-like growth factor binding protein
in situ hybridization
kilobase pair
kilodalton

human prostate cell
monoclonal antibody
macrophage colony stimulating factor
3-N-morpholino propanesulfonic acid

3-[4,5-Dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
optical density
polyacrylamide gel electrophoresis
human prostate cancer cell
phosphate buffered saline
polymerase chain reaction
platelet-derived growth factor
prostate specific antigen
parathyroid hormone

phosphatidylinositol-3 kinase subunits
Quantitative competitor polymerase chain reaction
radioimmunoassay
revolutions per minute
reverse transcription-polymerase chain reaction
ribozyme
standard deviation

sodium dodecyl sulfate
standard error

Serum free conditioned medium
human neuroblastoma cell

-

simian virus 40

transforming growth factor
N,N,N1, N-tetramethylethylene diamine
thyroid hormone
melting temperature
5' untranslated regions

ABSTRACT

IGF-II EXPRESSION IN HUMAN TUMOR TISSUES AND HUMAN
IGF-IIRIBOZYME ACTION

Zhaodong Xu

Insulin-like growth factors(IGFs) are potent mitogens for a variety of cancer cells
in vitro. In breast, prostate and neuroblastoma cancer cells, it has been suggested that

IGF-II plays a paracrine/autocrine role. However,information on cell-type -specific
IGF-II expression in vivo is limited. In situ hybridization and immunohistochemistry
were carried out to determine the cell type expressing IGF-II in different tumor
tissues. Both IGF-II mRNA and protein were localized to malignant cells, and

expression in the stroma was minimal in all the tumors. The data are consistent with

the hypothesis that cancer bell growth is regulated by IGF-II, and therefore IGF-II is a
potential target for cancer therapy.

RNA enzymes(ribozymes) which selectively cleave RNA targets via base-pairing
interactions can serve as therapeutic agents. We constructed IGF-II ribozymes and
stably transfected them in prostate cancer PC-3 cells. Single- and doublehammerhead ribozymes were synthesized and cloned into the pTZU6+27 or pcDNA
vectors. In vitro studies showed that both single- and double-ribozymes cleaved the
'140 bases and /or ~1 kilo bases IGF-II RNA substrates examined, while the mutant

ribozymes did not. Kcat/Km for cleaving the shorter IGF-II substrate by double

ribozyme and single ribozyme was 4772 and 1546 M"'S'\ respectively, suggesting
that double ribozyme was ~3 fold more efficient in cleaving the IGF-II substrate than

the single ribozyme in vitro. PC-3 stable transfectants expressing single ribozyme or
double ribozyme, under control of U6 promoter, reduced the endogenous IGF-II

mRNA and cell growth compared to mutant ribozyme transfectants. Similiarly, PC-3
stable transfectants expressing single ribozyme, under control of CMV promoter,

reduced the endogenous IGF-II mRNA and IGF-II protein secretion compared to
vector-control cells. Furthermore, PC-3 cells expressing single ribozyme grew poorly

under serum-free or 2% FCS conditions as judged by growth curves, supporting our
hypothesis that IGF-II plays a critical role in prostate cancer cell growth, and thus
provides a basis for developing a potential gene therapy for cancer.

I. INTRODUCTION

A. Insulin-like Growth Factor(IGF)System

The insulin-like growth factors (IGF-I and IGF-II) are single polypeptides with
structural homology to proinsulin (Rinderknecht and Humbel, 1978a; Rinderknecht
and Humbel, 1978b). They regulate proliferation and differentiation of a multitude of

cell types and are capable of exerting insulin-like metabolic effects(Rinderknecht and
Humbel, 1978a; Rinderknecht and Humbel, 1978b). For example,IGFs promote

important metabolic processes such as neurite outgrowth (Hepler and Lund, 1990),
steroidogenesis in ovarian granulosa cells(Recbler and Nissley, 1990), and

erytbropoiesis(Aron, 1992). Unlike insulin, they are produced by most tissues ofthe
body and are abundant in the circulation. Thus the IGFs have the potential to act by
endocrine as well as autocrine or paracrine mechanisms.

IGFs do function in conjunction with a complex IGF regulatory system. This IGF

regulatory system includes IGFs,IGF receptors, IGF binding proteins(IGFBPs)
(Nissley et al., 1984), and IGFBP proteases. The IGFs exert their effects at the
cellular level by binding to and initiating signal transduction cascades through the

type I IGF receptor, the type II IGF receptor and the insulin receptor. IGFBPs either
enhance or inhibit the interaction of the IGFs with these receptors (Baxter et al,

1986). These interactions are in turn regulated by IGFBP proteases, which are

important mediators ofIGFBP activity in biological fluids. During the last decade,
there has been increasing recognition of the role ofIGFs,IGF-I receptor and IGFBPs

in the control ofthe proliferation of cancer cells(Rechler and Nissley, 1990; Cullen et
al., 1992). The introduction of this dissertation provides an overview ofthe IGF
regulatory system, especially the role ofIGF system with the tumors and
subsequently focuses on developing a potential gene therapy using an IGF-II
ribozyme.

1. Insulin-like growth factors

(1) Insulin-like growth factor-I(IGF-I)

The human IGF-I gene is located on chromosome 12 and is approximately 90 kb

in length (Tricoli et al., 1986; Sussenbach et al, 1989). Two mRNA transcripts(IGFlA and IGF-IB) produced by alternative splicing are expressed in a defined pattern in
most tissues during pre- or post-natal development. The highest expression is
observed in adult liver(Han et al., 1988). Growth hormone(GH)is a major regulator,
enhancing IGF-I gene expression in liver and cartilage(Hynes et al., 1987). In
addition to GH,other hormones and trophic factors affect IGF-I expression. Thyroid

hormone(TH)(Wolf et al., 1989), EGF(Rogers et al., 1991), parathyroid hormone

(PTH)(Linkhart et al., 1989), cortisol(McCarthy et al., 1989) affect IGF-I expression
or GH-induced IGF-I expression. IGF-I stimulates proliferation and differentiation of
cells in many tissues, including rat and human bone(Rosen et al., 1994).
(2) Insulin-like growth factor-II(IGF-II)

The human IGF-II gene contains nine exons distributed over 30 kb DNA and is
located on the short arm of chromosome 11 (Nielson et al., 1995; Sussenbach et al..

1989). Like IGF-I, the IGF-II gene is transcribed and processed into several different
mRNA species (4.8, 5.3, 6.0 kb)resulting from alternative promoter usage and
alternative RNA splicing (Daughaday et al., 1989). The human IGF-II gene generates

multiple mature transcripts with different 5'untranslated regions(5'UTRs)but
identical coding regions and 3'UTRs. In rats and mice, the level ofIGF-II in serum is

higher during fetal than during post-natal life(Brown et al., 1986), while in humans
and guinea pigs, a substantial concentration ofIGF-II remains in adult serum
(Daughaday et al., 1986). Hormones and tissue-specific factors regulate IGF-II gene

expression in selected tissues. Human ovarian granulosa cells in culture accumulate
IGF-II RNA and secrete IGF-II in response to follicle stimulating hormone(FSH),

chorionic gonadotropin and prolactin (Voutilainen et al., 1987). Primary human
adrenal cells respond to adrenocorticotrophic hormone(ACTH)by increasing steadystate levels ofIGF-Il mRNA(Voutilainen et al., 1987). The mechanisms involved in
the regulation ofIGF-II expression are not completely understood. Nielson et al.
(1990) have shown that among several IGF-11 mRNA species, only mRNAs

containing the non-coding exon 6 are translated into polypeptide, suggesting that
translational competency for lGF-11 is determined by the 5'-untranslated region
(5'-UTR). IGF-II promotes cellular proliferation, differentiation and glucose
metabolism (Rosen et al., 1994).

2. IGF Receptors

The biological effects ofIGFs are mediated through IGF receptors on the cell
surface. There are two structurally and functionally distinct IGF receptors.
(I)Type I IGF receptor

The type I IGF reeeptor binds to IGF-I and IGF-II with equally high affinity(Sakano
et al., 1991; Casella et al., 1986). The type I IGF receptor is a disulfide bond linked
heterotetrameric protein (a2P2)in which the a subunit (~130 kDa)contains the
ligand binding domain and the P subunit(~90 kDa)contains a transmembrane
domain and an intracellular domain with tyrosine kinase activity (Ullrich et al., 1986;
LeBon et al., 1986; Rubin et al.,1995)(Fig. 1). The type I IGF receptor gene is

located on chromosome 15 (Ullrich et al., 1986). From the cDNA sequence, it was
found that the insulin and IGF-I receptor tyrosine kinase domain shared 84%

sequence identity (Ullrich et al., 1985). Several lines of evidence suggest that the
IGF-I receptor can mediate the effects of both IGF-I and IGF-II(Rechler et al., 1990).
Comparison of dose-response curves ofIGF-I and IGF-II for stimulating cell
proliferation in cultured human cells has revealed that higher concentrations ofIGF-II
are required to produce a response equivalent to that produced with IGF-I, suggesting
that the majority ofresponses to IGFs are mediated through the IGF-I receptor rather
than the IGF-II receptor (Rechler et al., 1990). A monoclonal antibody (aIR-3)

against the IGF-I receptor blocks either IGF-I -stimulated or IGF-II-stimulated [^H]thymidine incorporation into DNA in human fibroblasts in culture (Flier et al..
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1986;Van-Wyk et al., 1985). Sakano et al.,(1991) used site-directed mutagenic

procedures to express mutants ofrecombinant IGF-II, and the mutant IGF-II specific
to IGF-IR, not the ones specific to IGF-IIR, stimulate DNA synthesis and glycogen

synthesis. These results indicate that both IGF-I and IGF-II can act through the IGF-I
receptor to stimulate cell growth.
(2) Type IIIGF receptor

The type II IGF receptor binds IGF-II with a 100 fold higher affinity than
IGF-I and does not bind to insulin(Czech et al., 1989). The type II IGF receptor is

distinct from the type I and insulin receptor in that it consists of a single polypeptide
chain(~220 kDa)and is structurally identical to the mannose-6-phosphate(Man-6-P)
receptor(Oshima et al., 1988) which recognizes mannose-6-phosphate residues on

acid hydrolases and targets these enzymes to the lysosomes(Lobel et al., 1988).
The IGF-II/Man-6-P receptor is a transmembrane glycoprotein. The receptor
does not have intrinsic kinase activity but can be phosphorylated(Mogan et al.,

1987). Evidence indicates that N-linked glycosylation is required for proper folding
ofthe protein portion ofthe receptor and the carbohydrate can be removed without
adversely affecting the IGF-II binding function(MacDonald et al., 1985). Treatment
of cells with insulin increases the cell surface IGF-II receptor number by causing a

shift in receptors from a large intracellular pool to the cell surface in adipocytes(King
et al., 1982). The IGF-II/Man-6-P receptor cycles continuously between the cell
surface and intracellular compartments. The expression ofIGF-II/Man-6-P receptors

in various rat tissues is developmentally regulated and similar to the developmental
pattern of serum IGF-II(Moses et al., 1980) and tissue IGF-II mRNA expression

(Brown et al., 1986), suggesting an important role for IGF-II and the IGF-II/Man-6-P
receptor in fetal growth and development.
3. IGFBPs

There is a family of proteins that specifically bind to the IGFs. It has been

proposed that binding to the IGFs increases their stability and modulates their
biological activities (Baxter et al., 1986). The first indication that IGFBPs existed
came from the observation that the IGFs circulate as part of a 150 kDa complex in
human plasma. This complex could be dissociated by acid treatment into an IGF and
a 50 kDa IGFBP. The function of the 150 kDa IGFTGFBP complex in adult human

plasma was to prolong the half-life ofIGFs in the circulation (Nissley et al., 1984). In
the 1970s, it was directly demonstrated that the IGFs in most body fluids and in
media conditioned by cultured cells were complexed to proteins that bound IGF-I and
IGF-II(Hintz et al., 1977; Hintz et al., 1980; Zapf et al., 1975; Megyesi et al., 1975).

In the mid 1980s, a powerful technique, called ligand blotting, was introduced which
greatly facilitated the identification of more IGFBPs(Hossenlopp et al., 1986). To
date, six IGFBPs (designated IGFBP-1 through IGFBP-6) have been purified and
characterized from body fluids and from conditioned media in different cell lines.
cDNA clones and genomic clones for six IGFBPs have been isolated and

characterized (Shimasaki et al., 1991). The protein sequences determined directly or

deduced from cDNA nucleotide sequence demonstrated that the IGFBPs are a family

of closely related proteins. Amino acid sequences ofthe N- and C-terminal regions of
the six IGFBPs are highly conserved (Shimasaki et ah, 1991). Promoter regions of
the human IGFBP-1,-2, -3, -5 and rat IGFBP-1,-2, -3, -4, -5 and -6 genes have been

cloned and partially characterized (Suwanichkul et ah, 1990; Brown et al., 1990;
Binkert et ah, 1992; Cubbage et ah, 1990; Allander et ah, 1994; Zhu et ah, 1993).
The binding affinities of each IGFBP for IGF-I or IGF-II are different. IGFBP-1,
-3, -4 bind to IGF-I and IGF-II with similar affinity, and IGFBP-2,-5, -6 bind to IGF-

II with higher affinity (Martin et ah, 1986; Mohan et ah, 1989; Rechler et ah, 1990;
Roghani et ah, 1991). Among these IGFBPs,IGFBP-3 has an inhibitory effect which
is IGF-independent(Oh et ah, 1998), whereas its stimulatory effects are associated
with facilitation ofIGF action (El-Badey et ah,1989; Van den Hooff et ah, 1991; Ellis
et ah, 1994; Cullen et ah, 1995; Christofori et ah, 1994; Rogler et ah, 1994; Bates et

ah, 1995). A recent study done by Rajah et ah,(1997)showed that IGFBP-3 induces
apoptosis through a novel pathway independent of either p53 or the IGF receptormediated cell survival pathway and that IGFBP-3 mediates TGF-pi induced

apoptosis in PC-3 cells. By binding with these proteins, serum IGFs have a half life
of 12-15 hours compared with 10-12 min for the free peptides. The large complex
probably functions as a serum IGF reservoir. This is important because unlike other
hormones,IGFs are not stored in cells, but are secreted as soon as they are

synthesized.

(1)IGFBP-1

IGFBP-1 was purified from human amniotic fluid (Drop et al., 1984), placenta

(Bohn et al., 1980), endometrium (Bell et al., 1986) conditioned medium from Hep
G2 hepatoma cells (Rechler et al., 1990), etc. IGFBP-1 cDNA clones were isolated
from libraries established from human decidua, placenta, liver and Hep G2 cells

(Rechler et al., 1990). The complete amino acid sequence of human IGFBP-1 was
deduced from the cDNA sequence and confirmed by direct sequencing ofthe purified

IGFBP-1 protein. The human IGFBP-1 is a 25.3 kDa protein with 234 amino acids
(Lee et al., 1988; Brinkman et al., 1988; Luthman et al., 1989). Sequence analysis
demonstrated that IGFBP-1 contains 18 cysteine residues which are conserved in
IGFBPs 1-5 and are thought to stabilize the tertiary structure. The human IGFBP-1

gene is located on chromosome 7 and is 5.2 kb long (Brinkman et al., 1988). The
transcribed mRNA from this gene is a single 1.55 kb mRNA transcript (Alitalo et al.,
1989)in human liver(Brewer et al., 1988), and some breast cancer cells(Clemmons

et al., 1990). The human IGFBP-1 promoter has been well characterized. It contains
a TATA sequence, a CAAT box and a response element for the transcription factor,
hepatic nuclear factor 1 (HNF-1)(Suwanichkul et al., 1990).
(2)IGFBP-2

IGFBP-2 was purified from MDBK bovine kidney cells(Rechler et al., 1990),

human serum (Zapf et al., 1990), etc. cDNA clones encoding IGFBP-2 have been
isolated from libraries established from adult rat liver(Margot et al., 1989), bovine

MDBK cells(Upton at al., 1990), Hep G2 hepatoma cells(Zapf et al., 1990), etc. The
human and rat IGFBP-2 amino acids are 80% similar and the molecular masses are

31.4 and 29.6 kDa for human and rat, respectively(Brown et al., 1989). IGFBP-2
gene is located on chromosome 2 and is 40 kb in length(Agarwal et al., 1991;

Ehrenborg et al., 1991). mRNA from this human gene is a single 1.38 kb transcript.
IGFBP-2 has been detected in adult human brain and liver (Binkert et al., 1989), adult

rat brain, testes, ovary(Margot et al., 1989). The IGFBP-2 promoter contains three
SPI binding sites (Binkert et al., 1992).
(3)IGFBP-3

IGFBP-3 has been purified from multiple sources including porcine serum

(Walton et al., 1989), rat serum (Zapf et al., 1988), human plasma(Martin et al.,
1986), etc. Human IGFBP-3 is a 38.5-41.5 kDa to 45 kDa N-glycosylated protein
(Zapf et al., 1988; Yang et al., 1989). The human IGFBP-3 gene is located on

chromosome 7 and spans 8.9 kb (Ehrenborg et al., 1990). The gene encodes a single
2.5 kh mRNA(Wood et al., 1988). The IGFBP-3 promoter has been cloned and
contains a TATA box, AP-2 and SPI sites(Cubbage et al., 1990). IGFBP-3 is the
main carrier ofIGF-I and -II in serum. At least 95% of the total concentration of

IGF-I and IGF-II in the serum is bound to IGFBP-3(Baxter et al., 1989). The
remainder is bound to IGFBP-1,-2, and -4. Less than 1% ofthe total is free under

normal conditions. IGFBP-3 can either enhance or inhibit the metabolic or mitogenic
effects ofthe IGFs, depending on the cell type and the study conditions(Mohan,

1993; De Mellow et al., 1988). In addition, it may increase the half-life ofIGFs by

serving as a local reservoir from which IGFs can be continuously released into the
local environmnent by autocrine or paracrine actions (Bautista et al., 1990; Schmid et
al., 1989).

(4)IGFBP-4

IGFBP-4 is a 24 kDa binding protein purified from the conditioned medium of

human prostate carcinoma PC-3 cells (Perkel et al., 1990), human colon carcinoma
HT-29 cells (Culouscou et al., 1991), human glioblastoma T-98G cells(Camacho et

al., 1992), human serum (Kiefer et al., 1991), etc. IGFBP-4 cDNA clones were
isolated from rat liver (Shimasaki et al., 1990), human placenta(Shimasaki et al.,

1990), human osteosarcoma TE89(LaTour et al., 1990)cDNA libraries. Mature
IGFBP-4 contains 233 (rat) or 237(human) amino acid residues. There are 18

cysteine residues and two additional cysteine residues that are not present in other
IGFBPs. The human IGFBP-4 gene is located on chromosome 17 and is 15 kb long.

The gene has a 1.8 or 2.2 kb mRNA transcript(LaTour et al., 1990; Shimasaki et al.,
1991; Camacho et al., 1992). The function ofIGFBP-4 is inhibitory. It inhibited the
binding ofIGF-II to the type IIIGF receptor (Perkel et al., 1990) and cell

proliferation(Amamani et al., 1993)in MC3T3 mouse osteoblasts.
(5)IGFBP-5

IGFBP-5 is a 29 kDa protein that was purified from human hone (Bautista et al..
1991), cerebrospinal fluid (Binoux et al., 1991) and glioblastoma T98G cells

(Camacho et al., 1992). The human and rat IGFBP-5 contains 252 amino acid
residues and shares 97% amino acid sequence identity. IGFBP-5 cDNA clones were

isolated from human placenta(Shimasaki et al., 1991), osteosarcoma(Kiefer et al.,

1991). The gene was located on human chromosome 2(Shimasaki et al., 1991), the
transcripts are multiple, ranging from 5 to 6 kb.
(6)lGFBP-6

IGFBP-6 was purified from normal and transformed human lung fibroblasts
(Martin et al., 1990; Forbes et al., 1990), human serum (Zapf et al., 1990) and rat

serum (Shimasaki et al., 1991). The protein from fibroblast is 32-34 kDa(Martin et
al., 1990), 30-32 kDa from CSF(Roghani et al., 1991) and 28-30 kDa from human
serum (Zapf et al., 1990). IGFBP-6 cDNA was isolated from rat and human
osteosarcoma libraies (Kiefer et al., 1991). IGFBP-6 is expressed in human breast
cancer cells(Sheikh et al., 1993), transformed and untransformed fibroblast cells

(Martin et al., 1994), human adult liver, human osteosarcoma cells and human brain
(Kiefer et al., 1991). The expression ofIGFBP-6 is increased by TGF-P and agents
that increase intracellular cAMP concentrations. A distinguishing characteristic of
IGFBP-6 is its 20 to 100 fold preferential affinity for IGF-Il over that for IGF-1

(Martin et al., 1990; Forbes et al., 1990; Roghani et al., 1991; Bach et al., 1992; Bach

et al., 1993), suggesting that IGFBP-6 has a speeial role in modulating lGF-11 actions.

B. IGFs System and tumors

(1) Type I and Type IIIGF Receptors

It is increasingly recognized that the IGF-I receptor(IGF-IR) plays a fundamental
role in cell growth control and malignant transformation and is an important inhibitor
of apoptosis (Baserga et al., 1997). IGF-IR is highly expressed in a variety of human
tumors including breast cancer(Papa et al., 1993). Expression ofIGF-IR is required
for transformation by SV40 T antigen, bovine papillomavirus, activated ras, raf, and
v-src. When activated by IGFs,IGF-IR transmits a signal to at least four major
substrates, IRSl,IRS2, GrblO, She(Rubin et al., 1995)(Fig. 2). Other downstream
effectors include ras, raf-1, and mitogen-activated protein kinase(MAPK).

Strategies using dominant negative mutants ofIGF-IR, antibodies to IGF-IR, or
antisense directed against IGF-IR mRNA have shown that decreased or aberrant

receptor expression is associated with a reversal of the transformed phenotype with
induction of apoptosis(Werner et al., 1997; Rubin et al., 1995).

Overexpression of the normal human IGF-IR in NIH 3T3 cells leads to liganddependent alteration in cell morphology, colony formation in soft agar and

tumorigenicity in nude mice(Kaleko et al., 1990). IGF-IR deficient mice show
severely diminished growth (Liu et al., 1993). Whereas mouse fibroblasts that
overexpress IGF-IR have reduced growth factor requirements in vitro and

demonstrate decreased susceptibility to apoptosis (Sell et al., 1995).
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An involvement oftype IIIGF receptor in cancer is less clearly understood. The
IGF-II receptor(IGF-IIR)is a single-chain transmembrane protein identical to the
mannose-6-phosphate receptor. It is clear that this receptor can mediate uptake and
degradation ofIGF-II. By this means, it can indirectly affect IGF-II/IGF-IR

mitogenic response. De Leon et al.(1996) hypothesized that, in a cell overexpressing
IGF-II, the routing of lysosomal enzymes might be altered based on a previous
observation that IGF-II inhibits the cellular uptake of a lysosomal enzyme by

inhibiting binding to the IGF-II/mannose 6-phosphate receptor. Another recent study
showed that the IGF-II receptor may he directly involved in carcinogenesis. Ishiwata

et al.(1997)found that the IGF-IIR is overexpressed in a significant number of
human pancreatic cancers, indicating that IGF-IIR may contribute to the pathobiology
of pancreatic cancer.
(2) IGF expression in tumors

IGFs may play a part in neoplastic transformation and metastasis. Strong
evidence exists that a variety oftumors have the molecular machinery for the

production ofIGFs. By dot-blot and Northern blot analysis, investigators have found
much higher concentrations ofIGF-II messenger RNA in Wilms' tumors than in
normal kidney(Reeve et al., 1985; Scott et al., 1985). Subsequent studies have
established that increased IGF-II mRNA is associated with a variety of human

tumors, including embryonic(Wilms' nephrohlastoma, rhabdomyosarcoma.

hepatoblastoma)(Reeve et al., 1985; Scott et al., 1985; Hoppener et al., 1988;

Haselbacher et al., 1987; Daughaday et al., 1988; Daughaday et al., 1989; Koufos et
al., 1984), mesenchymal (fibrosarcoma, leimyosarcoma, hemangiopericytoma,

liposarcoma)(Yee et al., 1988; Reeve et al., 1985; Little et al., 1987; Tricoli et al.,
1986; Ron et al., 1989), neuroendocrine(pheochromocytoma, neuroblastoma), and

epithelial(colon, hepatic, breast and prostate) tumors(Lowe et al., 1989; El-Badry et
al., 1989; Cariani et al., 1988; Su et al., 1989; Tennant et al, 1996). The increased

expression ofIGF-Il mRNA in tumors is generally assumed to result in increased
synthesis of bioactive IGF-II protein. However,in some cases, IGF-II and IGF-II
mRNA are discoordinate. Haselbacher et al.(1987)reported that Wilms' tumors

expressed high levels ofIGF-II mRNA,but that levels ofimmunoreactive IGF-II in
the tumor did not differ from those in normal kidney. By contrast,

pheochromocytomas had 20-fold increased IGF-II protein but only 4-fold increased
IGF-II mRNA. Schofield et al.(1989) described a sarcoma expressing high levels of

IGF-II mRNA,but having reduced levels ofimmunoreactive IGF-II in cystic fluid

from the tumor or in plasma. The basis for these differences remains to be elucidated.

Experimental systems using transgenic mice have provided valuable information
on the potential role ofIGF-II in carcinogenesis. In transgenic mice expressing the
simian virus-40 large T-antigen(Tag) under the control ofthe insulin gene regulatory

region, the initial proliferative switch is correlated with focal activation ofIGF-II.
Reduced IGF-II expression by transfection with an antisense oligonucleotide to the
IGF-II mRNA impairs tumor cell growth in vitro, and transgenic mice homozygous

for a disruption ofthe IGF-II gene develop tumors with reduced malignancy and a
higher incidence of apoptosis in vivo (Christofori et al., 1994). Until now, most
studies have focused on the importance ofIGFs in controlling the proliferation of

previously transformed cells, however, evidence is now starting to accumulate that
components of the IGF signal transduction system may play a role in the
transformation process itself. One report involving transgenic mice, in which IGF-II

expression was targeted to the liver under the control ofthe major urinary protein
promoter, showed that the mice developed diverse varieties oftumors after 18 months
of age (Rogler et al., 1994). Transgenic mice, in which expression ofIGF-II was

targeted to the mammary gland by placing it under the control of the sheep plactoglobulin promoter, were shown to develop an excess of mammary tumors (Bates
et al., 1995). These two studies are highly in agreement and are the first in vivo

experiments to suggest a direct role for IGFs in the malignant transformation of cells.
Although the evidence that components ofthe IGF signal transduction system can be
involved in cell transformation is compelling, the mechanisms involved are not

known. Two possible explanations are that: the main function ofIGF-II is to increase
cell survival thereby allowing somatic mutations to accumulate in oncogenes or tumor

suppressor genes, and that the IGF signal transduction system itself could be

responsible for increased proliferation and the malignant transformation of cells.

(3)Autocrine /paracrine actions ofIGFs
IGFs are potent mitogens for a wide variety oftumor cell types and have been
identified as major autocrine or paracrine growth factors in a number of cancers

(Daughaday et al., 1990). That is, tumor cells with functional IGF receptors may he
able to enhance their own growth by synthesis of endogenous IGFs or by exogenous
IGFs secreted from stromal cells surrounding tumor eells (Fig. 3). For example, it has

been suggested that IGF-II may serve as a growth promoter in breast cancer in an
autocrine/paracrine manner while IGF-I may serve as a paracrine regulator in normal
and cancerous breast tissues (Singer et al., 1995).

Overexpression ofIGFs is thought to contribute to tumor cell proliferation in an
autocrine manner, which has been suggested by the experiment that mitogenic activity
ofcancer cells can he inhibited by monoclonal antibody aIR-3 against the IGF-I

receptor. These cell lines include small cell lung carcinoma (Gansler et al 1988),
rhahdomyosarcoma cells, and others (El-Badry et al., 1990). This provides evidence
that the production ofIGFs by these cells is the critical factor in stimulating
mitogenesis in serum-free medium.

A paracrine role ofIGFs has also been suggested for some cancers including
breast and prostate cancers. The prominent stromal reaction seen in many breast
earcinomas led to the speculation that stromal cells play a role in breast cancer

pathogenesis(Van den Hooff et al., 1991). The identification of genes that are
seleetively expressed in the stroma of malignant breast lesions has recently provided
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new insights into the molecular basis of stromal-epithelial interactions. It has been
suggested that IGFs mediate stromal-epithelial interactions in human breast cancer

(Ellis et al., 1994; Cullen et ah, 1995). Similarly, Byrne et al.(1996)reported that

IGF-II produced by prostatic stromal cells act on epithelial cells, leading to increased
proliferation. The role ofIGFs in the development and maintenance of prostate
cancer is less clearly defined.
(4)IGFBPs

IGFBP and IGFBP protease may also play an important role in cancer

development. Kanety et al.(1993)found that IGFBP-2 is increased while IGFBP-3 is
decreased in patients with prostate cancer, with a good correlation with serum
prostate-specific antigen, which is a IGFBP-3 protease. The results suggest that

IGFBPs may be involved in growth modulation of prostate malignancy and that
alterations in their serum levels may act as a marker for prostate cancer. Ho et al.

(1997)found that in active prostate carcinoma, serum IGFBP-2 level is elevated while
in benign prostatic hyperplasia(BPH),IGFBP-2 levels are not. Serum IGFBP-2
levels closely parallel those of prostate-specific antigen and probably reflect the

prostate carcinoma burden. IGFBP-3 is known to block IGF action and inhibit cell
growth. IGFBP-3 has been proposed to act by sequestering free IGFs or, possibly, act
via a novel IGF-independent mechanism(Oh et al., 1998). Supporting its role as a

primary growth inhibitor, IGFBP-3 production is increased by cell growth-inhibitory
agents, such as transforming growth factor-beta (TGF-beta), and the tumor

suppressor gene p53. Rajah et al.(1997)demonstrated that, for the first time, a novel
function oflGFBP-3 as an apoptosis-inducing agent and showed that this action is
mediated through the IGF receptor-independent pathway. In the p53 negative
prostate cancer cell line, PC-3, the addition of recombinant lGFBP-3 resulted in a

dose-dependent induction of apoptosis. These membrane-associated molecules may
serve as receptors that mediate the direct effect ofIGFBP-3 on apoptosis
(5)IGF system in benign and cancerous prostate tissues
Prostate cancer is the most common cancer in adult men in the United States. The

incidence increases with age, and about 80% of prostate cancers are diagnosed after

the age of65 years (Carter et al., 1990). Although an autocrine role ofIGF-I in
prostate cancer cell growth was originally suggested (Pietrzkowski et al., 1993), there
has been substantial evidence which suggests that IGF-11, but not IGF-I, may play an
important role in paracrine or autocrine regulation of normal and hyperplastic prostate
growth(Dong et al., 1997) as well as prostate cancer cell growth. Angelloz-Nicoud et
al.(1995)reported that the autocrine role ofIGF-II via the type I IGF receptor in PC-

3 cell proliferation. IGF-II bioavaiability in this system is modulated by limited
lGFBP-3 proteolysis. Similarly, Figueroa et al.(1995)found that IGFBP-1, which

binds IGF-II with high affinity, inhibited IGF-II-induced monolayer growth and both

baseline and IGF-ll-induced anchorage-independent growth in prostate cancer cell
line, DU145. The data suggest IGF-II is an autocrine growth faetor instead ofIGF-I
in DU145 cells, and that the inhibition of this autocrine loop may represent a new

therapeutic strategy for prostate cancer. In an effort to understand the role ofIGFs in
prostate cancer cell growth, Fujita-Yamaguchi's group characterized the IGF system
components produced by human prostatic cancer cell-lines, LNCaP,DU145,and PC-

3, grown in serum-ffee medium (Kimura et al., 1996). They found that mRNA for
lGF-11 and receptors for lGF-1 and lGF-11 were detected in all three cell-lines. In
contrast to another published study (Pietrzkowski et al., 1993), only LNCaP cells
expressed a trace amount oflGF-1 mRNA. RIA revealed that all three cell-lines

produced measurable IGF-11 protein but not lGF-1 protein. DNA synthesis in PC-3

cells was significantly inhibited by the lGF-1 receptor-specific monoclonal antibody.
Further, we showed that by in situ hybridization significant levels oflGF-11 mRNA
expression were present in 63% of prostate tumors examined, and that lGF-11 mRNA
was localized to malignant cells (Li et al., 1998). Tennant et al.(1996)also reported
that IGF-11 mRNA is increased in human prostate carcinoma compared to benign

prostatic hyperplasia(BPH)while protein and mRNA for the type 1 IGF receptor is
decreased. It has been demonstrated that the levels oflGF-1, -11, and IGFIR mRNAs

in the prostate of old human subjects were 2- to 3-fold higher than those of young
control subjects, suggesting that the observed increase may also be an age-related

process(Bonnet et al., 1993). It is possible that the abimdant presence oflGF-11 in

the adult prostate may cause subtle alterations over time, leading to the development
of separate tumor foci.

BPH is the most common benign proliferative disorder of unknown etiology.
Boudon et al.(1996)suggested that IGF-II and the secreted forms ofIGFBPs,

depending on anatomical location within the organ, were important for the autocrine
regulation of normal and hyperplastic prostate growth. Dong et al.(1997)found that
IGF axis is critical for prostate cell growth and is abnormal in BPH. The elevated
expression ofIGF-II and type I IGF receptor genes in BPH is associated with the
decreased expression of Wilms' tumor gene WT-1,indicating that IGF system
components may also be involved in the development of prostatic hyperplasia.
(6) Loss ofimprinting in cancer

Genomic imprinting is defined as a gamete-specific modification causing
differential expression ofthe two alleles of a gene in somatic cells(Mitsuyoshi et al.,
1996). There are seven endogenous genes showing parental-specific monoallelic

expression. IGF-II(DeChiara et al., 1991), small nuclear ribonucleoprotein-

associated polypeptide (Leff et al., 1992), Ins 1,2(Giddings et al., 1994), U2afbp-sr
(Hatada et al., 1993) are expressed from the paternal allele whereas IGF-II receptor
(Barlow et al., 1991)and H19(Bartolomei et al., 1991) are expressed from the
maternal allele. WTl is expressed from the maternal allele or both (Jinno et al.,

1994). Recent evidence suggests that loss ofimprinting(LOI)is associated with gene
activation in cancer(Yun et al., 1998).

Preferential loss of heterozygosity(LOH)of a specific parental allele in several
childhood tumors provides indirect evidence for genomic imprinting in cancer and

has led to a popular hypothesis that an aberrant imprint inactivates one allele of a
tumor suppressor. LOH was first discovered in retinoblastoma and in Wilms' tumor

(Fearon et al., 1984; Reeve et al., 1984). The gene associated with Wilms' tumor
(nephroblastoma)is a potential tumor suppressor gene wtl. This gene encodes a
DNA binding protein, WTl,which binds to the major fetal IGF-II promoter and
functions as a potent suppressor ofIGF-II transcription(Dong et al., 1997; Wemer et
al., 1993; Wemer et al., 1995; Qing et al., 1996; Vincent et al., 1996). IGF-II thus

appears to he part of a rate-limiting step in multistage oncogenesis, promoting tumor
growth and malignancy.
Both the IGF-II and HI9 gene are located on chromosome I Ip15.5 in close

proximity to each other, and are imprinted on different parental alleles. LOI leading
to the biallelic expression ofIGF-II and HI9 genes has recently been reported in a
variety of tumors(Wu et al., 1997; Kim et al., 1997)and in Beckwith-Wiedemarm
syndrome (Joyce et al., 1997). These data suggest that LOI leading to overexpression
ofIGF-II plays an important role in carcinogenesis. Jarrard et al.(1995)reported that
in prostate, both the cancer and the normal peripheral zone tissue have a pronounced
biallelic expression ofIGF-II gene. They hypothesized that this loss ofimprinting

has a good correlation with the development of prostate cancer. Sun et al.(1997)
introduced a IGF-II transgene into the mouse genome by using embryonic stem cells,
which led to transactivation ofthe endogenous IGF-II gene. Overexpression of

IGF-II resulted in most ofthe symptoms of Beckwith-Wiedemarm syndrome.

including polyhydramnios, prenatal overgrowth, fetal and neonatal lethality, and
disproportionate organ overgrowth. These studies provide new insights into how

IGF-II gene expression is affected by LOI under pathophysiological conditions.
C. Ribozymes

1. Discovery of Ribozymes

Cech and colleagues(1982)discovered an intervening sequence or intron, in the
precursor of RNA of T. Thermophila could excise itself from a pre-RNA and in the
process ligate the flanking exon sequences together to generate a mature rRNA. The
RNA intron accomplishes splicing without aid from proteins, and the excised intron
retains the ability to create or break phosphodiester bonds present in RNA. Altman

and colleagues demonstrated that the RNA component ofthe ribonucleoprotein
enzyme RNase P is the eatalytic subunit of this tRNA processing enzyme. The
RNase P ribozyme processes precursor tRNAs with multiple turnover and is not

changed during processing. Thus, catalytic RNAs are not limited to single turnover
intramolecular reactions but, like protein enzymes, are capable of multiple turnover.
2. Ribozyme classification
(1) Hammerhead Ribozymes

This group ofRNAs share a two-dimensional structural motif known as the
"hammerhead" which has been shown to be sufficient to direct site-specific cleavage.

The hammerhead structure consists of three base-paired stems (helices I, II, and III),

which flank the susceptible phosphodiester bond, and two single-stranded regions.

which are highly conserved in sequence (Forster et ah, 1987; Unlenbeck et ah,1987).
Extensive mutagenesis has revealed the important nucleotides and functional groups
for efficient catalysis. Haseloff and Gerlach(1988) proposed a model whereby the
hammerhead domain is separated such that the substrate RNA contains just the

cleavage site, and the ribozyme contains the other conserved nucleotides ofthe
catalytic core. Mutagenesis has revealed that the target site can be any NUX

sequence where X = A,C, or U(lUB system) and N is any nucleotide (Haseloff et ah,
1988; Perriman et ah, 1992)(Fig. 4). The sequence ofthe arms ofthe ribozyme

aligns the catalytic core to the target site via complementary base pairing. A minimal
catalytic cycle of a hammerhead ribozymes has been proposed (Fig. 5). McCall et ah,
(1992)have determined the minimum core sequence required for catalytic activity
which has resulted in the "minizyme". The model of Haseloff and Gerlach has
allowed the design of specific endoribonucleases. This work encouraged others to

design trans-acting ribozymes. There are two main applications for the ribozymes'
ability to cleave the RNA and thereby inhibit the expression of a specific gene
selectively. One is to work as a tool for molecular biology (in vitro manipulation of
RNAs)and the other is to inactivate gene transcripts in vivo, for example, as antiviral
agents. The use ofribozymes for both applications has become possible with the

development of chemical synthesis ofRNA,with or without modified nucleosides
and the identification of suitable expression vectors.
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(2) Hairpin Ribozyme

A second small catalytic domain is the "hairpin'structure, which has four helical
domains and five loops(Hampel et ah, 1989; Hample et ah, 1990; Berzal-Herranz et

ah, 1993). Two helices ofthe hairpin domain form between the substrate and
ribozyme, and this allows the design and specificity of binding for trans-acting
hairpin ribozymes. The hairpin ribozyme has a more complicated substrate

requirement than the hammerhead ribozyme, but despite this, any RNA ofinterest is
expected to have numerous potential target sites. The summary ofthe base
requirements for a hairpin ribozyme is shown in Fig. 6.
(3) Hepatitis delta virus

HDV genomic and antigenomic RNAs contain a self-cleavage site hypothesized
to function during rolling circle replication(Wu et ah, 1989). The sites in HDV are

postulated to have a related secondary structure, three models of which have been
proposed: cloverleaf(Wu et ah, 1989); pseudoknot (Perrotta et ah, 1990), and
axehead (Branch et ah, 1991), none of which is similar to the catalytic domains

previously described. Like the other ribozyme motifs, the HDV ribozymes require a
divalent cation(Wu et ah, 1989), and cleavage results in products with 2', 3'-cyclic
phosphate and 5'-0H termini(Branch et ah, 1991). Investigation of trans-cleavage
with the HDV ribozymes are limited.
(4) Group I intron

Group I intron self-splicing (in vitro) in the absence of protein was first observed
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for the intervening sequence ofthe nuclear 26S rRNA gene in Tetrahymena
thermophila(Kruger et al., 1982). Splicing proceeds by two consecutive transesterifieation reactions(Zaug et al., 1983). The reaction is initiated by a nucleophilic
attack by the 3'-hydroxyl of a guanosine (or a phosphorylated derivative: GMP,

GDP,or GXP)at the phosphodiester bond between the 5'-exon and the intron 5'-splice

site). The new 3'-hydroxyl group ofthe 5'-exon than initiates a second nucleophilic
attack, on the phosphodiester bond between the 3'-exon and the intron (the 3'-splice
site). This results in ligation of the exons and excision ofthe intron. Shortened
versions of the Tetrahymena IVS have been shown to be true enzymes in vitro, for

example, as a restriction endoribonuclease(Azug et al., 1986) and as a template-

dependent polymerase(Kay et al., 1987). The structure of group I intron is shown in
Fig. 7.
(5) Group II introns

Group II introns splice by way oftwo successive phosphate transfer reactions. In
the first step, the 2'-0H group of an intramolecular branch point adenosine attacks the

phosphodiester bond at the 5'-splice site, producing the free 5'-exon and a splicing
intermediate, the intron-3'-exon. The second step involves cleavage at the 3'-splice

site by the 3'-OH ofthe 5'-exon. Simultaneously, the exons are ligated and the intron
lariat, with a 2', 5'-phosphodiester bond,is released. The ability ofthe group II
introns to bind the 5'-exon specifically has been exploited to encourage the IVS to

catalyze reactions on exogenous substrates. It has been shown that a group II intron
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can ligate ssDNA to RNA,and another cleave a ssDNA substrate (Augustin et al.,
1990).

(6) Ribonuclease P

Ribonuclease P(RNase P)is the ubiquitous endoribonuclease that processes the

5'-end of precursor tRNA molecules(Darr et al., 1992). It cleaves specific bonds to
produce 5'-phosphate and 3'-OH termini, and in vitro requires a divalent metal ion.
RNase P consists of a protein moiety and an RNA moiety. It was discovered that, at
least in bacteria, it is the RNA moiety that is the catalyst(Guerrier-Takada et al.,

1983). Several studies have now shown that RNase P can be modified into cleaving
any desired substrate (Forster et al., 1990)(Fig. 8).
3. Ribozyme delivery

Ribozymes must be introduced into the target cell. There are now two general
mechanisms that exist for introducing catalytic RNA molecules into cells, one is to

exogenously deliver the preformed ribozymes, and the other is endogenously express
the ribozymes from a transcription unit.
There are at least three methods for the delivery of preformed ribozymes into the

cells, they are liposomes, electroporation, or microinjection. Efforts have been made
to overcome the lack of stability ofintroduced RNAs by using modified nucleotides,
2'-fluoro- and 2'-amino-(Pieken et al., 1991), or 2'-0-metbyl- (Paolella et al., 1992),
mixed DNA/RNA molecules(Snyder et al., 1993), or by the addition of terminal

sequences(such as the bacteriopbage T7 transcriptional terminator) at the 3'-end of
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the RNA to protect against cellular nucleases (Sioud et al., 1992). Endogenous

expression can be achieved by inserting ribozyme sequences into the untranslated
regions of genes transcribed by RNA polymerase II(pol II), which have strong
promoters, such as the SV40 early promoter(Cameron et al., 1989), CMV promoter
(Mabieu et al., 1994), the actin promoter (Sarver et al., 1990), or a retroviral long

terminal repeat(LTR)(Koizumi et al., 1992). Ribozymes have also been inserted into
the anticodon loop oftRNA transcribed by RNA polymerase III(pol III) as well as
linked to downstream of promoter sequences derived from the human UI snRNA and
U6 snRNA (Bertrand et al., 1997).

4. Ribozymes as antineoplastic agents

Ribozymes can be used to target the replication of oncogenic DNA virus, for

example, ribozymes have been shown to interrupt the LMP gene ofEBV,which is
necessary for persistence, episomal replication, and transformation ofinfected B-cells
(Joske et al., 1993). Other viruses included HBV (Yoffe et al., 1992), papillomavirus
and the newly discovered y berpesvirus associated with kaposi's sarcoma(Chang et
al., 1994). In the last 3-4 years while our ribozyme projects were in progress, an

increasing number of studies describing neoplastic conditions being targeted by
vectors expressing ribozymes have been published. For example, the bcr-abl
translocation messages present in Philadelphia chromosome-positive adult chronic
myelogenous leukemia has been targeted by ribozymes in vitro (Leopold et al., 1995;

Leopold et al., 1994). A recent report by Wright et al.,(1998) demonstrated a 53%

decrease in bcr-abl mRNA levels in a clone induced to express Rz, compared with its
uninduced control. Phenotypic analysis of this clone also revealed a 63% decrease in
colony-forming ability and a 43% inhibition of cell proliferation following ribozyme
expression. Morphological analysis of the cells showed a slight increase(2.5% to
15%)in the number of cells undergoing apoptosis. These results suggest that

ribozyme was effective in suppressing bcr-abl gene expression within a cellular
environment and altering the leukemic nature of a CML cell line. Dorai et al.,(1998)
reported development of a hammerhead ribozyme against BCL-2. II. Ribozyme
treatment sensitized prostate cancer LNCaP cells to apoptotic agents. Ribozyme

transfection and subsequent application of apoptotic stimuli, such as, serum starvation

or phorbol ester treatment, caused a 30% increase in cell death by apoptosis compared
with these apoptotic stimuli alone. The results obtained strongly support the ability of
a potential anti-bcl-2 ribozyme therapy to synergize with other agents in inducing
apoptosis of hormone-resistant human prostate cancer cells. Ribozymes have also
been shown to inhibit H-ras transformation of fibroblasts in vitro, as well as in vivo

(Feng et al., 1995; Funato et al., 1994; Ohta et al.,1994; Kasgani-sabet et al., 1994;
Tone et al., 1993; Kashani-sabet et al., 1992), as evidenced by reduction in tumor

growth and aggressiveness in murine models. Yokoyama et al.(1997) also reported
using a hammerhead ribozyme to modulate the c-fms-oncogene in an ovarian

carcinoma cell line. Co-expression of macrophage colony-stimulating factor(MCSF)and its receptor (c-fms) is often found in ovarian epithelial carcinoma.

suggesting the existence of autocrine regulation of cell growth by M-CSF. In order to
block this autocrine loop, Yokoyama et al.(1997) have developed hammerhead

ribozymes against c-fms mRNA. The ribozymes were able to cleave an artificial cfms RNA substrate in a cell-free system, and in TYK-nu cells that expressed M-CSF

and its receptor. The transfectant showed a reduced growth potential. The expression
levels of c-frns protein and mRNA in the transfectant were clearly decreased with the

expression ofribozyme RNA compared with that of an untransfected control or a
transfectant with the vector without the ribozyme sequence.

Other strategies for using ribozyme-expressing vectors in the treatment of cancer
include the introduction into malignant cells oftransgenes designed to obviate
resistance to antineoplastic drugs, to prevent resistance or restore susceptibility to
conventional chemotherapeutic agents. Ribozymes against the human multidrug
resistance gene(mdr) have been described (Bertram et al., 1995; Kobayashi et al.,
1994a; Kobayashi et al., 1994b). Czubayko et al.(1996)used a hammerhead

ribozyme targeted to secreted growth factor pleitrophin and successfully modulate

melanoma angiogenesis and metastasis. Another in vivo experiment using an antiCAPL ribozyme demonstrated reversal ofthe metastatic phenotype of human tumor
cells(Maelandsmo et al., 1996).
5. Factors affecting hammerhead ribozyme cleavage in vitro

A consensus sequence defined as the catalytic core of hammerhead ribozymes has
been described by Forster and Symons,(1987). Single changes in the consensus

region have shown some effect on catalytic efficiency on every base within the 14
conserved sites (Ruffher et al., 1990). Any change in the consensus sequence of the

ribozyme catalytic core causes some, often significant, loss in catalytic activity
(Ruffner et al., 1990).

Magnesium is needed to stabilize the 5'-oxygen leaving group (Taira et al., 1990).
The reason for that is probably its ability to stabilize the tertiary structure ofthe
hammerhead complex. Dahm et al.(1991)found that spermidine can lower the
concentration of magnesium required for cleavage, suggesting spermidine can replace
magnesium in stabilizing the active ribozyme structure.

Looking for the most favorable sequences for nonconserved bases in the ribozyme
structure has not been successful. Ruffher et al.(1989) have shown that ribozyme
activity can vary up to 1000-fold due to the changes in nonconserved bases. The
difference between ribozyme activity with differing numbers of bases in stems and /or

loops are difficult to generalize as they may be sequence-specific (Rufftier et al.,
1989; Heidenreich et al., 1992).

6. Problems underlying the effective use ofribozymes as therapeutic agents
Intracellular experimentation with ribozymes leaves many factors uncontrolable.
Many factors, such as magnesium concentration, cellular pH, degradation ofthe
ribozyme, co-localization ofthe target and ribozyme, secondary or tertiary structure
of endogenous target RNA or ribozyme ,as well as RNA-binding proteins, can affect

the activity ofribozymes in vivo. This indicates that the application ofthis cchnology
is not as straightforward as simply expressing a complementary sequence in vivo.

Given the complexity of eukaryotic gene expression, there are numerous factors
that can impact on ribozyme efficacy, including the rate oftranscription ofribozyme

genes, the stability of the ribozyme, the in vivo rate of hybridization, the location of
the ribozyme gene relative to the target gene in the host genome, and the site at which
the ribozyme functions(Denhardt et ah, 1992). Furthermore, the cleavage capacity of
the ribozyme provides an additional complexity related to achieving ideal conditions
for both substrate RNA cleavage and release of products. Traditional efforts to
enhance the efficiency ofribozyme-mediated suppression have been directed towards

increasing the intracellular concentration and stability ofribozymes, with the aim of
maintaining high ratios of these sequences relative to the target mRNA. There are
two major approaches to overcome the degradation ofribozymes, and hence enhance
the stability ofribozymes. One is to chemically modify the RNA,thereby decreasing
degradation in vivo and the other is to add sequences or structures that naturally
increase transcript stability. Other strategies have attempted to determine the general
regions ofthe target mRNA accessible to ribozyme regulation and the optimal lengths
for the flanking arms ofthe ribozymes(Murray et al., 1992). These efforts to
improve upon the efficiency ofribozymes have resulted in some success.
With the recent advances in techniques for in situ detection of specific DNAs or
RNAs inside intact cells, much attention has been focused on the location of

individual genes and mRNAs and the organization ofthe machinery required for
transcription, processing, and transport within the eukaryotic nucleus (Carter et ah,
1994). Genomic DNA sequences may occupy specific sites within the nucleus
(Blobel et ah, 1985; Marshall et ah, 1997) and mRNAs have been shown to be

localized to specific foci (Spector et ah, 1993) and transported along specific tracks in
both the nucleus(Lawrence et ah, 1989; Xing et ah, 1993) and the cytoplasm
(Lawrence et ah, 1986). Moreover, some specialized mRNAs undergo cellular
localization via specific cis-acting RNA sequences and cellular localization
machinery(Mowry et ah, 1995). Co-localization oftarget RNA and ribozyme is
crucial to ribozyme activity within cells. Localization ofRNA within the cell
depends on compartmentalization. Fulton et ah (1982) and Spector et ah (1993) have
respectively presented evidence for a compartmentalized organization ofthe nucleus

and cytoplasm. Targeting of a ribozyme to its substrate that are compartmentalized in
the nucleus and/or cytoplasm remains to be overcome before establishment of
ribozyme therapy.

D. Overview

In the United States, prostate cancer is the most common solid tumor malignancy
in men and second to lung cancer as the leading cause of cancer deaths in this group.
Prostate cancer progression involves the shifting of cells from androgen-dependent
growth to an androgen-independent state, sometimes with the loss or mutation ofthe
androgen receptors in prostate cancer cells. Both autocrine and paracrine pathways

are up-regulated in androgen-independent tumors and may replace androgens as
primary growth stimulatory factors in cancer progression. These growth factors
include fibroblast growth factor, IGFs,EGF,TGF alpha, retinoic acid, vitamin D3,
and the TGF beta families. Even though prostate cancer is responsible for 40,000
deaths per year, a screening program like the prostate-specific-antigen(PSA)test is a
matter of controversy because scientific evidence is lacking that early detection
decreases morbidity and mortality. Furthermore,PSA test detects the signal of
cancers already under way, hut it can not identify men at high risk of getting prostate
cancer before they develop the disease. Recent epidemiology studies reported that
IGF-I levels in plasma are associated with prostate cancer risk (Chan et al., 1998).

Drugs which can lower IGF-I levels may thus help lower a man's risk of prostate
cancer. Decisions oftreating prostate cancer are difficult to make because ofthe
nature of prostate cancer and because it tends to occur in older men who often have
multiple, competing medical illnesses. In general, localized cancer is best treated

with surgical removal ofthe prostate gland or radiotherapy. Hormone deprivation

therapy is the primary method of controlling metastatic prostate cancer. At present,
chemotherapy can be used to treat disseminated prostate cancer. However, there is no

effective method of treating hormone-independent prostate cancer. Gene therapy

using molecular tools to down-regulate autocrine and paracrine pathways of growth
stimulatory factors, like IGFs, in androgen-independent tumors may thus lead to a
logical promising strategy.

Dr. Fujita-Yamaguchi's Laboratory has been interested in insulin and IGFs and
the relationship between IGFs and tumors. They have laid ground work by

examining the structure ofinsulin and IGF-I receptors. IGFs have been previously
reported to promote prostate cell and neuroblastoma cancer cell growth via the IGF-I
receptor in an autocrine/paracrine manner. Dr. Fujita-Yamaguchi's group and others
recently showed that IGF-II, hut not IGF-I, is produced in established human prostate
cancer cell lines, and suggested an autocrine regulation ofDU145 and PC-3 cell

growth by IGF-II(Figueroa et al., 1995; Angelloz-Nicoud et ah, 1995; Kimura et ah,
1996). Since IGF-II expression in prostate tumors and other tumors is not quite clear,
it was necessary to determine whether epithelial or stromal cells express IGF-II in
prostate tumors in vivo in order to understand the possible autocrine role ofIGF-II in
prostate cancer growth.

Li et ah (1998), recently used in situ hybridization and immunohistochemistry
methods to determine whether epithelial or stromal cells express IGF-II in prostate

tumors in vivo (chapter II). The results showed that IGF-II is expressed in over

50% of prostate, breast, and bladder cancer tissues. In all positive cases, the

expression is localized to malignant cells. These data are consistent with the

hypothesis that cancer cell growth may be regulated by IGF-II. This information has
led us to consider IGF-II as a target for molecular manipulation toward the
establishment of novel cancer therapy.

Of new molecular technologies developed recently, we have chosen the ribozyme

strategy to manipulate IGF-II gene expression. Ribozymes have been increasingly
used in treating human diseases, including HIV (Rossi, 1998). To test our hypothesis
that prostate cancer cell growth is regulated by IGF-II, ribozymes against human
IGF-II were constructed and intracellularly expressed in the androgen-independent
prostate cancer PC-3 cell lines.

E. Goals and Objectives of the Project

Ribozymes are catalytic RNAs that can be useful for manipulation of gene
expression, which may lead to a useful tool in gene therapy. Ribozymes have two
properties, first, site-specific recognition ofRNA,similar to antisense
oligonucleotides, and second, RNA substrate destruction via site-specific cleavage.
Hammerhead ribozymes are small, thus easy to handle. Successful application of
hammerhead ribozymes to target genes of interest have been reported. The goals of

my dissertation were 1)to evaluate IGF-II expression in different tumor tissues,
breast, prostate, bladder, and paraganglioma by in situ hybridization and
immunohistochemistry, 2)to design ,construct and express an IGF-II ribozyme, 3)to

compare cleavage kinetics of different ribozymes, and 4)to determine whether antiIGF-II ribozymes can delay growth in cancer cell lines.
In this dissertation, two human cancer cell lines were utilized, human prostate
cancer cell line PC-3, and human neuroblastoma cell line SK-N-AS. Both cell lines

can express IGF-II as an autocrine factor.
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A. Abstract

Insulin-like growth factors(IGFs) are potent mitogens for a variety of cancer cells
in vitro. A paracrine/autocrine role ofIGF-II in breast and prostate cancer cell growth
has been suggested. Information on cell-type specific IGF-II expression in vivo in the

breast and prostate is, however, limited. Thus, cell types expressing IGF-II mRNA
and protein in tumors were identified by in situ hybridization and
immunohistochemistry. Of36 prostate, 17 breast, and 10 bladder cancers as well as 9
paraganglioma tissues examined,IGF-II was expressed in more than 50% of prostate,

breast, and bladder tumors and in 100% of paraganglioma tumors. Expression levels
ofIGF-II were highest in the paraganglioma and bladder followed by prostate and
breast tumors. In all the tumors expressing IGF-II, both mRNA and protein were
localized to malignant cells and expression in stroma was minimal. Furthermore,
since previous studies indicated that an incompletely processed form of 15 kDa IGFII exhibits higher mitogenic potency than the completely processed 7.5 kDa IGF-II,
the quantity and size ofIGF-II proteins expressed in these tumors were analyzed by
Western immunoblotting. Greater expression of 15 kDa relative to 7.5 kDa IGF-II

was clearly demonstrated in all six prostate cancers and in half of the two breast and

four bladder cancers examined. The results were consistent with the hypothesis that
the 15 kDa form ofIGF-II expressed in cancerous cells may contribute to autocrine
cancer cell growth in vivo.

B. Introduction

Insulin-like growth factor (IGF)-II is a single chain polypeptide of67 amino acid
residues, that has amino acid homology with IGF-I and proinsulin(Humbel, 1990).

Both IGF-I and IGF-II bind to the IGF-I receptor with high affinity, which initiates
mitogenic responses in the cell(Daughaday and Rotwein ,1989; Perdue et ah, 1991;
Baserga, 1995). IGFs are potent mitogens of breast cancer cells, and an
autocrine/paracrine regulation of breast cancer cell growth has been suggested (Huff
et ah, 1986; Osbome et ah, 1989; Cullen et ah, 1990). Most of the established breast

cancer cell lines do not express IGF-I or IGF-II(Yee et ah, 1988), and it has been

proposed that IGFs expressed in tumor stroma stimulate the growth of neighboring
tumor epithelium by paracrine mechanisms(Hogan et ah, 1987, 1988; Manni et ah,
1994; Singer et ah, 1995). Despite the strong emphasis on paracrine actions ofIGF-II
in breast stromal-epithelial interaction in vivo, stromal IGF-II expression has not been

clearly demonstrated by previously published in situ hybridization(ISH)studies
(Manni et ah, 1994; Singer et ah, 1995; Giani et ah, 1996).
It was originally reported that IGF-I is responsible for autocrine growth of human
prostate cancer cell lines including androgen-dependent LNCaP as well as hormoneindependent DU145 and PC-3 cells (Pietrzkowski et ah, 1993). We and others more

recently showed that IGF-II, but not IGF-I, is produced in those established human
prostate cancer cell lines, and suggested an autocrine regulation of DU145 and PC-3

cell growth by IGF-II(Kimura et al., 1996; Figueroa et al., 1995; Angello-Nocoud
and Binoux, 1995). It is now necessary to determine whether epithelial or stromal
cells express IGF-II in prostate tumors in vivo towards understanding a possible
autocrine role ofIGF-II in prostate cancer growth.
The objective ofthis study was to identify cell types expressing IGF-II mRNA
and protein in tumors, particularly in breast and prostate cancers. We also included
bladder cancer as well as paraganglioma since IGF-II expression in the former has not
been analyzed and since high levels ofIGF-II protein expression in the latter have

previously been demonstrated by immunohistochemistry(IHC)(Suzuki et al., 1989).
We then analyzed the size and the level ofIGF-II protein expressed in prostate,
breast, and bladder tumors by Western immunoblotting to determine whether high Mr
IGF-II is expressed in these tumors. The 15kDa IGF-II has been found in most

patients with nonislet cell tumors that develop hypoglycemia(Daughaday 1990;
Daughaday and Trivedi, 1992; Enjoh et al., 1993). The present study provides
evidence that cancerous cells, but not stromal cells, specifically express IGF-II in
vivo, and suggests that the high Mr IGF-II is more abundant than 7.5 kDa IGF-II in
these cancers than benign tissues.

C. Materials and Methods

Multi-tumor blocks(MTBs)and cell cultures: MTBs of human prostate, breast.
bladder cancers and paragangliomas used were formalin-fixed, paraffin-embedded

archives which had been prepared and stored by the Department of Anatomic

Pathology, City of Hope Medical Center (Battifora, 1986). Human prostate cell
lines, LNCaP,DU145,and PC-3, were obtained from American Type Culture

Collection (Rockville, MD),and cultured in RPMI1640 supplemented with 10% fetal
calf serum,2 mM L-glutamine, and 1 mM sodium pyruvate. Human neuroblastoma

cell line, SK-N-AS, which can grow continuously in serum-free medium by autocrine
growth stimulation by IGF-II, was kindly provided by Dr. Carol Thiele, Pediatric
Branch, NCI, and were grown as described (El-Badry et al., 1991). Cells grown in a

75 cm^ flask were collected, formalin-fixed, and paraffin-embedded, from which
sections were made for ISH experiments.

In situ hybridization: An approximately 1 kb fragment ofcDNA encoding the human

precursor IGF-II(911 to 2067 nt.. Dull et al., 1984) was subcloned into pBluescriptll

KS(+)(Stratagene, San Diego). ^^S-Labeled sense and antisense probes were
transcribed from the plasmid in the presence of ^^S-UTP using Stratagene's RNA
transcription Kit (Stratagene, San Diego) and purified with NucTrap push columns
(Stratagene, San Diego). IGF-I cRNA probe of413 bases was also prepared from
pBluescript vectors containing cDNA fragments of 130 to 542 nt.(Jansen et al.,

1983). The probes were reduced to approximately 150 nucleotides by alkaline
hydrolysis.

ISH was performed essentially as described by Angerer et. al.(1987). Briefly,
sections on sialinized slides were baked at 80 °C for 1 h, deparaffinized in xylene and

rehydrated in graded ethanols. Following proteinase K treatment(30 min at 37 °C in
lOOmM Tris HCl, pH 8.0, 50 mM EDTA, 1 pg/ml proteinase K [Boeringer
Mannheim]), the tissue was acetylated in O.IM triethanolamine-HCl at pH 8.0 at
room temperature for 10 min. They were briefly washed in 2X SSC and dehyrdated
in ethanol. Twenty five pi of the hybridization mix(50% formamide,0.3M NaCl,
20mM Tris HCl, pH 8.0, ImM EDTA,IX Denharts, 10% dextran sulfate, 100 mM

DTT,500 pg yeast tRNA/ml, 1 pg of probe [10^ dpm] were added to each slide. The
slides were covered with plastic cover slips, sealed with rubber cement, and placed in

a humidified chamber at 46°C overnight. After removal ofthe coverslip, the slides
were rinsed 3 times with 4X SSC at room temperature, and then treated with RNase
solution(20 pg/ml RNase in 0.5M NaCl, lOmM Tris HCl, pH 8.0, ImM EDTA)at

37°C for 30 min. Following washing for 30 min at 37 °C in RNase A buffer(0.5M
NaCl, lOmM Tris HCl, pH 8.0, ImM EDTA),the slides were rinsed with 2 X SSC
for 30 min at room temperature and then in 0.1 X SSC at 55 °C. The slides were then
dehydrated through graded alcohols and air dried. Autoradiography was performed
using Kodak NTB-2 nuclear track emulsion, exposed for 3 weeks, and then following
developing, lightly counterstained with hematoxylin (H).

Monoclonal antibodies (rtiAbs): Anti-IGF-II mAb which was kindly provided hy Dr.

K. Nishikawa of Kanazawa Medical University is IgGj against rat IGF-II(Tanaka et
al., 1989). This is the same mAh as Amano mAh used hy Enjoh et al. (1993) and
anti-IGF-II mAh used hy others(Tang and Rogler, 1991; Teimant et al., 1996: Giani et
al., 1996). It hinds to human IGF-II, human IGF-I, and human insulin with affinities
of 100%, < 10%,and < 0.01%, respectively. Unless otherwise stated, this antibody

was used for IHC. Three mAhs against human IGF-II, 2H11,2BI1, and 1D4, which
do not crossreact with either human IGF-I or rat IGF-II(Enjoh et al., 1993) were
kindly provided hy Dr. K. Sakano of Daiichi Pharmaceutical Co. Ltd.
Immunohistochemistry: Studies were carried out with mAhs that are reactive in

routine paraffin sections. Four pm paraffin sections mounted on Prohe-on slides
(Biotek Solutions; Vantana, Tucson, AZ)were baked for 1 hr at 55 °C and then dried

overnight at 48 °C. They were subsequently deparaffmized in xylene, rehydrated in
graduated alcohols to distilled water, and loaded into a Techmate"^" Slide Holder and
placed into 10 mM citrate buffer, pH 6.0. Antigen retrieval was performed hy the

HIER (Heat Induced Epitopy Retrieval) method (Battifora et al., 1995). The slides
were steamed in 10 mM citrate buffer for 20 min and then allowed to cool for 5 min

using a household Black and Decker Steamer(model #HS90). The primary IGF-II
antibody was used at concentrations of 0.1-10 pg/ml as indicated, and incubated
overnight in a humid container. A modified ABC(Vector Elite Kit; Vector Lab.

Burlingam, CA)technique was used for detection with DAB as the chromogen and
the slides were lightly counterstained with Mayer's hematoxylin. All staining was
performed using a Bioteck Techmate 1000 Immunostainer (Biotek Solutions) with a
ABC detection system (Biotek Solutions).
Data analysis: The localization of hybridization or immunoreactivity in the tissues

after ISH or IHC experiments was examined by three individuals including one ofthe
experienced pathologists(G.K, Y.S., or S.W.). The intensity of hybridization was
scored on a 5-point scale according to the judgement of the same pathlogist(S.W.),
where 0 = no hybridization or staining, ± = some hybridization or staining but not
definitely positive, 1+ = weak hybridization or staining, 2+ = moderate hybridization
or staining, and 3+ = strong hybridization or staining.
Immunoaffinity concentration ofIGF-II in extracts oftumors: Immunoaffinity resins

were prepared by coupling anti-IGF-II mAb 2H11 to either formyl-cellulose or
CNBr-activated Sepharose 4B as previously described (Enjoh et al. 1993; FujitaYamaguchi et al., 1983). Immunoaffinity concentration ofIGF-II from tumors was

carried out as previously described (Enjoh et al. 1993). Briefly, -0.2 g of frozen
tumor tissues were extracted with 4 vol 87.5% (vol/vol) ethanol/I2.5% (vol/vol)2N
HCl to release IGF-II from IGF-II/IGF binding protein complexes. The supematants
were lyophilized, dissolved in 1 ml ofPBS containing 0.02% Tween, and incubated at

25°C for 3 hr with 30 pi of mAb 2H11-conjugated resin. After extensive washing

with PBS containing 0.02% Tween 20 and IM NaCl,IGF-II was eluted from the resin

with -20 |4,1 sodium dodecyl sulfate-polyacrylamide gel electrophoresis(SDS-PAGE)
sample buffer under nonreducing conditions.
Western immunoblot analysis: IGF-II extracted from tumors(~0.1g tissue equivalent)

was resolved by SDS-PAGE on a 15% gel under nonreducing conditions and
electrotransfered to PVDF membranes as described (Enjoh et al. 1993). The

membranes were blocked overnight at 4°C with 5%(wt/vol) skim milk in PBS

containing 0.05% Tween 20,incubated with 2 pg/ml mAb 2H11, and then with
biotinylated sheep anti-mouse IgG and streptavidin-HRP. The IGF-II-mAb

complexes were detected using the ECL system (Amersham, Arlington Heights,IL),
followed by exposure to X-ray films.
D. Results

IGF-II, but not IGF-I, is expressed in prostate cancer cell lines: IGF-II and IGF-I

mRNA expression in three prostate cell lines and neuroblastoma SK-N-AS cells as

positive control was examined by ISH. The results ofISH using the IGF-II cRNA
antisense probe and IGF-I cRNA antisense probe shown in Fig. 9 demonstrate that
IGF-II mRNA,but not IGF-I mRNA,is expressed in prostate cancer LNCaP,DU145,
and PC-3 cells as well as neuroblastoma SK-N-AS cells. The results confirmed our

previous study, in which both reverse transcriptase-polymerase chain reaction and
radioimmunoassay(RIA)were used(Kimura et al., 1996), and suggested potential
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pitfalls only associated with estimating IGF levels by RIA (Pietrzkowski et al, 1993).
IGF-II expression in prostate tumors: Of36 prostate cancer specimens examined,
IHC experiments revealed that 22 specimens expressed significant levels ofIGF-II
mRNA(>I+) with the IGF-II cRNA probe (Table 1 A). Fig. 10 shows H and E

staining(A)and darkfield photographs of a typical prostate tumor analyzed by ISH
using sense(B)and antisense(C)probes. While the sense probe only revealed
background signals, cancerous epithelial cells showed significantly elevated
hybridization signals with the antisense probe. Darkfield and brightfield photographs
ofISH results oftwo other prostate cancers are shown in Fig. 11A-D, which clearly

demonstrate that cancerous epithelial cells express IGF-II mRNA. IGF-II expression
was also seen in some ofthe benign epithelial cells adjacent to the infiltrating cancer

(Figs. IOC, 1 IE, and I IF). Of particular interest is the very intense staining ofIGF-II
mRNA as seen in Figs. 1 lE-H. This focal IGF-II expression, as indicated by open
arrows in Fig. 1 IE and G, was observed in benign glands adjacent to prostate cancers

(22% of 36 cancers examined) as well as one offour benign prostates examined
(Table IB). Figs. 1 lE-H represent typical focal IGF-II expressions in benign
epithelial cells in a prostate cancerous tissue and a benign prostate. A similar
observation to this one, the IGF-II expression in focal groups of cells in neoplastic
nodules of woodchucks, was also reported by Yang and Rogler(1991).
Immunostaining with anti-IGF-II mAb (10 pg/ml)indicated that 11 of 19 prostate

Table 1. Expression ofIGF-II mRNA in benign and malignant prostates as measured
by in situ hybridization.

A. IGF-II mRNA expression in benign and malignant prostate.
IGF-II mRNA expression level
samples
-

±

1+

2+

3+

Benign prostate:

^

2

1

0

I*

0

Malignant prostate:

36

2

12

8

9

5

IGF-II positivity in malignant

14(39%)

22(61%)

prostates

* Focal expression (see below and Fig. 3E and G).

B. Focal IGF-II mRNA expression in benign epithelial cells in benign and
malignant prostate.
Total number examined

Focal IGF-II mRNA

Benign prostate

I (25%)

Malignant prostate

8(22%)
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cancers examined showed the presence ofIGF-II in good accordance with IGF-II
mRNA expression (data not shown). In summary, high levels oflGF-11 mRNA

expression was detected in cancerous epithelial cells and the expression in stroma was
minimal(Figs. IOC and 11A-D). Of note, however, was that lGF-11 expression was
seen in benign epithelial cells (Figs. IOC and 1 lE-H).
lGF-11 expression in breast cancer: Of 17 breast cancers examined, nine showed

positive for lGF-11 mRNA expression by ISH (Table 11). One set of results showing
H and E staining, ISH with sense or antisense lGF-11 probe demonstrate that lGF-11
mRNA is clearly expressed in cancerous epithelial cells but not in stromal cells

(Fig. lOD-F). Relatively high expression oflGF-11 was also detected in benign
epithelial cells of breast cancers as seen in Fig. lOF. Immunostaining with anti-lGF11 mAb using 10 |4,g/ml revealed the presence oflGF-11 protein in five of nine
specimens examined. The protein staining was seen in good accordance with lGF-11
mRNA expression (data not shown).
lGF-11 expression in bladder cancer and paraganglioma: Ten bladder cancers were

examined for expression oflGF-11 by ISH and IHC. Although only three bladder
cancers were definitely positive for lGF-11 mRNA by ISH,IHC using anti-lGF-11
mAb at 0.1 pg/ml revealed that lGF-11 protein was detected in five bladder cancers
including two tissues that were negative for lGF-11 mRNA. Fig. 12A,B, C, and D

represent one set of results, i.e., H and E staining, IHC,ISH using the sense probe.

Table 2. Expression ofIGF-II mRNA in breast tumor tissues.
Breast

Number

IGF-II mRNA expression level

cancer

of

-

±

2

I-i-

samples
infiltrating
ductal

14

5

Lobular

2

1

Intraductal

1

2

I

IGF-II

positivity

17(100%) 8(47%)

9(53%)

*

9^

m

.'

:.qp^
•

• ,»:•'■■

K- .v,. .
3»'

••

s^'l' :.. m^- 1*..
■

»

■*'

•«•

*■

.

g

'

^
s».

»

?-^'vI
I

and ISH using the antisense probe, respectively. The results not only clearly revealed
abundant expression ofIGF-II mRNA and protein in cancerous cells not in stroma,
but also demonstrated that IGF-II mRNA and protein expression in bladder cancers
was higher than in prostate and breast cancers.

Consistent with the previous observation by Suzuki et al.(1989), we found that of

nine paragangliomas examined, all were positive for IGF-II protein by IHC using
anti-IGF-II mAb at a concentration of O.I pg/ml. ISH experiments revealed good
expression levels ofIGF-II mRNA in 8 ofthe specimens. Results of one

paraganglioma specimen are shown in Fig. 12E, F, G,and H(H and E staining, IHC,
ISH using the sense probe, and ISH using the emtisense probe, respectively). IGF-II

protein and mRNA expression is seen in tumor cells by both IHC (Fig. 12F)and ISH
(Fig. I2H), respectively.
Neutralization ofIGF-II immunostainins by exogenously added IGF-II: In order to

verify that the positive signal obtained with IHC while using the anti-IGF-II mAb is
in fact due to IGF-II expressed in the cancerous cells, the IHC experiments were

performed in the presence ofIGF-II(100 times in molar excess ofthe antibody).
Both paraganglioma and bladder cancers that were positive by IHC did not show any

positivity in the presence of excess IGF-II, confirming that the cells stained with this
antibody express the IGF-II protein.
IHC using other anti-IGF-II mAb: Although the anti-IGF-II mAb used in this study.
as well as other studies (Suzuki et al., 1989; Yang and Rogler, 1991; Tennant et al..

1996; Giani at al., 1996), binds to human IGF-II, it is known to be specific for rat

IGF-Il and also crossreacts with human IGF-I to some extent. In contrast, newly
introduced mAbs 2B11,2H11, and 1D5 were shown to be specific for human IGF-II
and not to crossreact with IGF-I at all(Enjoh et al., 1993). In addition, their antigenspecificities may differ from that ofthe original anti-IGF-II mAb. We thus examined
whether the new mAbs detect the IGF-II protein expressed in breast, prostate, bladder

and paraganglioma differently from those detected with the original anti-IGF-II mAb.
Immunostaining with these mAbs at a concentration of2 pg/ml revealed positive for
IGF-II protein in bladder and paraganglioma. The cells stained were basically similar
to those achieved by the original anti-IGF-II mAb at a concentration of O.I pg/ml.

The intensity ofthe staining was, however, significantly lower than that stained with
the original anti-IGF-II mAb even using 2BII which gave the highest intensity
among the three new mAbs. Under this condition, prostate and breast epithelial cells
were not stained probably due to much lower affinities ofthose mAbs for IGF-II than
that ofthe orignal anti-IGF-II mAb.
IGF-II Western immunoblotting ofIGF-II isolated from prostate, breast, and bladder

tumors: Increases in the ratio of high Mr IGF-II to 7.5K Mr IGF-II occur in most

patients with nonislet cell tumors that develop hypoglycemia(Daughaday, 1990;
Daughaday and Trivedi, 1992; Enjoh et al., 1993). In order to determine the
abundance and size heterogeneity ofIGF-II protein expressed in the tumor tissues

described above,6 prostate, 2 breast, and 4 bladder cancers, 2 benign prostate, one
prostate BPH,and 2 benign bladder tissues were subjected to Western

immunoblotting. Tissues were acid-treated to remove IGF binding proteins and
concentrated by immunoaffinity adsorbants (2H11-Sepharose) prior to Western
immunoblot analysis according to the procedures described by Enjoh et al.(1993).
The results including 5 cancerous and 3 benign tissues are shown in Fig. 13. The

amounts ofIGF-II protein detected by this procedure appeared to be between 13 and

130 ng since 130 ng, but not 13 ng, ofIGF-II was seen in the control experiments
(Fig. 13, lanes 1 and 2, respectively). Thus, except one tissue shown in Fig. 13 lane
11 which contained >130 ng IGF-II per ~0.1 g wet tissue, all the positive IGF-II
signals from the tissue samples are assumed to have contained 13-130 ng IGF-II per

~0.I g wet tissue. In addition to the completely processed 7.5 kDa IGF-II, high Mr

IGF-II with apparent Mr I5K was always detected in all the cancerous tissues
examined except one breast cancer (Fig. 13, lane 4), which showed a very weak signal
probably due to low protein level in this predominantly fatty specimen. Fig. 13, lanes
9 and 10 represents the results of cancerous and benign tissues ofthe same bladder,

respectively, which are consistent with the hypothesis that cancerous tissues express

higher levels of high Mr IGF-II. It should be noted that the prostate BPH shown in
Fig. 13 lane 7 clearly expressed a high Mr IGF-II.
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In summary, relatively more abundant expression of high Mr IGF-II to that of7.5K
Da IGF-II was clearly seen in all six prostate cancers, one BPH,one oftwo benign

prostates, one oftwo breast cancers, and two offour bladder cancers but not in two
benign bladders examined.
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E. Discussion

In the present study, we analyzed expression ofIGF-II in human prostate, breast,
bladder, and paraganglioma by ISH,IHC, and immunoblotting. All the results are
tablulated in Table III. We showed ; i) IGF-II was expressed in >50% of breast,
prostate, and bladder cancer tissues as well as 100% of paragangliomas that have been

examined by ISH and IHC; ii) in all positive cases, the expression ofIGF-II was
localized to malignant cells; iii) in prostate and breast cancers, IGF-II mRNA
expression was localized to epithelial cells. IGF-II protein was detected weakly by

ISH in epithelial cells expressing IGF-II mRNA;iv) in bladder cancers, both IGF-II
protein and mRNA were highly expressed; v)in paraganglioma, high levels ofIGF-II
protein were detected, while mRNA levels were moderate; and vi) an incompletely
processed 15 kDa IGF-II, which is thought to be more mitogenic than 7.5 kDa IGF-II
(Perdue et al., 1991), was expressed in almost all ofthe cancerous tissues and the

higher ratio of 15 kDa/7.5 kDa IGF-II was seen in >50% of those tissues as detected
by Western immunoblot analysis. Thus, we have not only confirmed the previous
observation by Suzuki et al. (1989)that IGF-II protein is highly expressed in

paraganglioma, but also added new information on IGF-II mRNA expression in this
tumor. To the best of our knowledge, possible involvement ofIGFs in bladder cancer
has not been reported. The present study revealed that -50% of bladder cancers

Table 3. Summary ofIGF-II expression in prostate, breast, bladder, and
paraganglioma tumors as detected by ISH,IHC, and Western Immimoblotting.
IGF-II mRNA

detected by ISH

IGF-II protein
detected by

Higher ratio of 15
kDa/7.5 kDa IGF-

Prostate cancer

22/36,61%

11/19,58%

II detected by
Immunoblotting
5/5, 100%

Breast cancer

9/17, 53%

5/9, 56%

1/2, 50%

Bladder cancer

3/10, 30%

5/10, 50%

2/4, 50%

Paraganglioma

8/9, 89%

9/9, 100%

Not determined

IHC

expressed IGF-II at the highest expression levels among the four different tumors that
we examined. Furthermore, this study showed the ratio of 15 kDa and
7.5 kDa IGF-II proteins expressed in breast, prostate, and bladder cancer tissues
which have not been previously reported.

The measurement ofIGF-II in tissue samples is much more difficult as compared
to that in sera of patients with nonislet cell tumor hypoglycemia as previously

reported (Daughaday and Trivedi, 1992). This is mainly due to the presence ofIGF
binding proteins which affect an accurate estimation ofIGF-II protein levels as well
as low IGF-II protein levels in tissue homogenates. To overcome these problems,

acid treatment followed by IGF-II concentration by IGF-II mAb affinity resins was
necessary before Western blot analysis. Enjoh et al.(1993) previously analyzed the

quantity and ratio of 15 kDa and 7.5 kDa IGF-II proteins in sera and tumor tissues of
patients with nonislet cell tumor hypoglycemia by RIA and Western immunoblotting,
respectively. They showed ~300 ng ofIGF-II, of which more than 80% account for
15 kDa IGF-II, in -300 pi serum or -O.I g tumor tissue from 12 different patients
with nonislet tumor hypoglycemia including one patient each with breast and prostate
cancer. Their Western blot results revealed much higher quantities ofthe 15 kDa

IGF-II than our results, shown in Fig. 13, lanes 4-10. Approximately 10-fold higher
levels of 15 kDa IGF-II were detected in their samples compared to ours, except that

one bladder cancer specimen showed a high level of 15 kDa IGF-II protein (Fig. 13,
lane 11) which appears to be similar to the levels they detected. The low level of

IGF-II protein expression we observed is probably due to the difference in the sources
of cancer tissues used since the sera or tissues they analyzed were only from cancer

patients who were known to contain high levels of circulating IGF-II.
In breast cancer tissues, IGF-II mRNA was clearly detected in malignant
epithelial cells as well as in some benign epithelial cells. Previous studies, however,
have suggested that the overexpression ofIGF-II in breast stroma influences the
growth of cancerous epithelial cells by paracrine mechanisms(Hogan et al. 1987,

1988; Manni et al., 1994; Singer et al., 1995). Evidence to support this stromal
epithelial interaction includes in vitro as well as in vivo studies. For example,
increased establishment of tumor and increased growth of MCF-7 cells occurred
when the tumor cells were coinoculated with breast fibroblasts in athymic mice as

compared to injection with MCF-7 cells alone(Hogan et al., 1987). More recently.
Singer et al.(I995) and Gianti et al. (1996)reported that there were high levels of
IGF-II expression in stroma of many invasive breast cancers but not in normal breast
tissues by ISH. In our ISH experiments, malignant epithelial cells had stronger signal
than surroimding stromal cells, and IGF-II expression in the stroma was scattered and

focal. The morphology ofthe tumors illustrated in Fig. IB and E of Giani et al.

(1996)that did not express IGF-II are relatively well differentiated tumors. Their
more poorly differentiated tumors(Fig. IF and G)did show silver grains over tumor
similar to what we foimd. It is thus plausible that the differences in our results and
their results are due to the differentiation state of the tumors that we studied.

In the case of prostate cancer, our results are consistent with the findings by

others. Jarrard et al. (1995)showed intense staining of the prostate epithelium with a
biotinylated IGF-II oligonucleotide probe while showing that stromal cells appeared
to react with the IGF-II probe to a lesser extent than epithelial cells. Tennant et al.
(1996)showed that IGF-II mRNA was localized primarily to epithelial cells and that
IGF-II expression was significantly increased in adenocarcinoma compared to that in
benign epithelium. These observations with IGF-II expression in vivo are also
consistent with previous reports (Kimura et al., 1996; Figueroa et al., 1995; AngelloNocoud and Binoux, 1995), which suggested autocrine roles ofIGF-II in human
prostate cancer DU145 and PC-3 cells. We noticed a peculiar focal expression as
well as an elevated expression ofIGF-II in benign epithelium ofthe prostate. It

should be noted, however, that the IGF-II expressing cancerous and benign epithelial
cells that we found were in the prostate of patients at ages 68 ± 6.8 years(n=38).
Since the levels ofIGF-I, IGF-II, and the IGF-I receptor mRNAs in the prostate of
advanced-age subjects were shown to be 2- to 3-fold higher than those of young
control subjects(Bonnet et al., 1993), it is also likely the observed increase in IGF-II

expression may be an age-dependent process.

Although prostate and breast cancers expressing IGF-II mRNA were positive for
IGF-II protein by IHC,the IGF-II mAb concentration required was 100 times higher
than stained IGF-II protein in paraganglioma and bladder tumors. Tennant et al.
(1996) also used the same conditions as ours to stain prostate tissues. This in fact

indicates a possibility that the IGF-II protein level is either very low, or unstable in
prostate and breast cancers. Alternatively, it is possible that the elevated IGF-II
mRNA expression in prostate and breast cancers may not lead to abundant IGF-II

protein expression. The human IGF-II gene consists offour promoters and nine
exons. The major promoters in fetal and nonhepatic adult tissues are P3 and P4, and
activation of each promoter seems to be dependent on the cell type of origin. De

Moor et al. (1994)examined differential polysomal localization of human IGF-II
mRNAs in five ofthe human tumor cell lines and in fetal liver, and reported that the
P3-derived mRNA is the most abundant whereas P2- and P4-derived mRNAs were

much lower in abundance. Interestingly, while P2- and P4-derived mRNAs were
found in the polysome fractions only, the most abundant P3-derived mRNA was

found predominantly in the untranslated fractions. Further investigation will be thus
needed to identify the IGF-II promoters used in cancerous and benign epithelial cells
by using specific probes for respective 5'UTR ofIGF-II transcripts.

In summary, our data is not only consistent with the hypothesis that cancer cell
growth may be regulated by IGF-II in an autocrine manner, but also supports the idea
that IGF-II may be a potential target for cancer therapy.
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III. MATERIALS AND METHODS

A. Materials

1. Cells.

The human prostate cancer cell lines PC-3,LNCaP,DU145, were obtained from
the American Type Culture Collection (Rockville,Md.), human neuroblastoma cell
line, SK-N-AS was kindly provided by Dr. Carol Thiele, Pediatric Branch, NCI.
2. Reagents

Acrylamide, bis-acrylamide and Bradford-dye reagent, TEMED (N,N,N'N',

-Tetramethylenediamine) and ammonium persulfate were purchased from Bio-Rad
Laboratories(Richmond, CA). Bacto-yeast extract and Bacto-tryptone were obtained
from DIFCO (Detroit, MI). Bovine Serum Albumin(BSA)were obtained from
Calbiochem Corp. (La Jolla, CA). Fetal calf serum was purchased from Irvine
Scientific. Inc.(Irvine, CA). G418 was purchased from GIBCO/BRL-life

technologies Inc. (Gaithersburg, MD). Guanidinium isothiocyanate was obtained
from Fluka Chemicals(Ronkonoma, NY). Klenow fragment of DNA Polymerase I
was from Pharmacia (Piscataway, NJ)or Promega(Madison, WI). MEGAscriptTM

kit were purchased from Ambion Inc.(Austin, Tx). Oligo primers were synthesized
by DNA/Peptides core facility of City of Hope medical Center.(Duarte, CA).
Proteinase K was purchased from Boeringer Mannheim. RNase- free DNase I was
obtained from GIBCO/BRL-life Technologies Inc.(Gaithershurg,MD). RNA

transcription kits were purchased from Stratagene(San Diego, CA). RNA Trizol

solution were purchased from GIBCO/BRL-life Technologies Inc.(Gaithersburg,
MD). RPMI 1640 medium was obtained from GIBCO (Santa Clara, CA). Seaplaque
agarose was purchased from FMC BioProducts (Rockland, ME). Superscript TMII
Reverse Transcriptase was obtained from GIBCO/BRL Life Technologies
Inc.(Gaithersburg, MD). T3 RNA polymerase, T7 RNA polymerase, T4

Polynucleotide Kinase, RNasin, restriction enzymes and buffers were from Promega

(Madison, WI)and GIBCO/BRL life Technologies Inc. (Gaithersburg, MD).
Trypsin-EDTA solution was purchased from Irvine Scientific. Inc.(Irvine, CA).
Other molecular biology reagents were obtained from Sigma Chemical Company (St.

Louis, MO),USB (Cleveland, OH)and Fisher Scientific (Tustin, CA). a-[^^P]-dCTP

(3,000 Ci/mmol), ^^S-UTP (3,000 Ci/mmol) and y-[^^P]-ATP (7,000 Ci/mmol) were
purchased from ICN Biomedicals Inc. (Costa Mesa, CA). Vent DNA polymerase was
from New England Biolabs Inc.(Beverly, MA).
3. Molecular Biology Solutions
Deionized formamide: Formamide was melted at room temperature and 50 ml was

deionized with 5 g AG 501 x 8 resin(BioRad)by stiring for 30 min at room

temperature. The solution was filtered twice with Whatman # 1 paper, aliquoted and
stored at -20 °C.

Denhart's 50 x stock: 1% ficoll, 1% polyvinylpyrrolidone, 1% bovine serum albumin.
The solution was then filtered through a disposable 0.22 micro Nalgene filter.

DEPC water: 0.1% diethyl-pyrocarbonate was added to double-distilled water
overnight. The treated water was then autoclaved.
Luria broth (LB): 0.1% Bacto-tryptone, 0.05% bacto-yeast extract, 0.1% NaCl,
pH7.1.

Methylene blue solution: 0.02% methylene blue and 0.3 m sodium acetate, pH 5.5,
stored in a dark bottle.

10 X MOPS: 0.2 M 3-(N-morpholino) propanesulfonic acid, 5 mm sodium acetate, 5
mM EDTA,pH 7.0.

Northern sample loading buffer: 720 pi deionized formamide, 320 pi 10 x MOPS,
260 pi formaldehyde solution(37% stock solution), 100 pi glycerol,4 mg
bromophenol blue,4 mg xylene cyanol and lOOpl DEPC water.
Pre-GIT solution: 4 M Guanidinium thiocyanate, 0.025 m sodium citrate and
0.5% n-lauryl sarcosine.

GIT solution: 360pl of 2-mercaptoethanol in 50 ml pre-GIT solution.
5 X first strand RT buffer: 0.25 M Tri-HCl, pH 8.3, 0.375 M KCl,0.015 M MgC12
10 X NEB Vent buffer: 0.1 m KCl,0.2 M Tris-HCl, pH 8.8, 0.1 M(NH4)2 804,0.02
m MgS04,1% Triton X-100.

20 X SSPE: 3.6 M NaCl, 0.03 m NaH2 P04,0.02 M EDTA,pH 7.4.
20 X SSC: 3.0 M NaCl and 3.0 M sodium citrate, pH 7.0.
50 X TAE:2 M Tris-acetate and pH 8.0, 0.05 M EDTA.

lOxTBE: 0.4 M Tris-HCl, pH 8.0, 0.4 m boric acid and 0.012 M EDTA,pH 8.3

TBE loading buffer: 20% glycerol, 80% 10 x TBE,0.4% bromophenol blue and 0.4%
xylene cyanol.
TE buffer: 0.01 M NaOH,0.01 M Tris-HCl, pH 8.0, 1 mM EDTA and 0.1% SDS
10 xTMDSE: 0.01 M Tris-HCl, pH 7.6, 0.1 M MgC12,0.01 M DTT, 1 mM
spermidine and 1 mM EDTA
4. Miscellaneous Materials

MagnaGraph nitrocellulose membrane was purchased from Micro Separations Inc.
(Westborough, MA). Nytran nylon membrane was purchased from Schleicher &
Schuell Inc. (Keene, NH). ART tips were purchased from Molecular Bio-products

Inc. (San Diego, CA). dNTP and NTP were purchased from Pharmacia (Piscataway,
NJ). Chroma spin-10 column were purchased from Clontech Inc.(Palo Alto, CA).
NucTrap push columns were purchased from Stratagene(San Diego, CA).
WizardTM Miniprep DNA purification columns were obtained from promega

(Madison, WI). Qiagen Plasmid maxi kits were purchased from Qiagen Inc.

(Chatsworth, CA). Culture dishes and polypropylene tubes were obtained from
Coming Glass Works(Coming, NY). Multi-well plates were from Costar

(Cambridge, MA). pBluescriptIISK(+) plasmid was purchased form Stragene(San
Diego). pTZU6+27 was kindly provided by Dr. J. J. Rossi of City of Hope, Duarte,
CA. Plasmid pcDNA3 was purchased from Invitrogen(San Diego, CA).
B. Methods

1. Plasmid Preparation

A single bacteria colony from an LB plate (1.5% agar in LB broth with
appropriate antibiotic) was inoculated into 10 ml of LB broth containing ampicillin
(100|ag/ml) and was grown overnight at 37°C with shaking. Overnight bacterial

suspension(10 ml)was then added to 10 to 500 ml of fresh LB containing ampicillin
and was incubated at 37°C overnight with vigorous shaking. The bacteria were
pelleted by centrifugation at 5,000 x g for 15 min at 4°C in a 250 ml polypropylene
bottle(100 to 500 ml)or 50 ml disposable tube(10 to 50 ml)in a Sorvall RC-2B

centrifuge(Du Pont, Newtown, CT). Plasmid DNA was recovered using an alkaline,
phenol extraction method or with Qiagen Kits.
(1) Alkali lysis preparation
Plasmid DNA preparation was prepared as described by Titus(1992). Briefly,
bacteria was pelleted by centrifugation from 100 ml ofthe overnight culture,

resuspended in 5 ml of TENS buffer by shaking until it became sticky. To this, 2.5 ml
of 3.0 M sodium acetate, pH 5.2 was added and shaken until the lysate cleared.
The cell lysate was centrifuged at 10,000 x g for 20 min at 4°C and the supernatant
was treated with RNase A (10p.g /ml)at 37°C for 10 min. To the supernatant, 10 ml

of 0.1 M Tris-HCl(pH 8.0)-saturated ethanol/chloroform/IAA (24:24:1) was added.
The mixture was shaken, placed on ice for 5 min, and centrifuged as described above.
The supernatant was removed and 1/10 volume of3 M sodium acetate(pH 5.2) and
2 volumes of absolute ethanol(-20°C) was added to the upper aqueous phase. The

solution was mixed and placed on crushed dry ice for at least 1 h to precipitate the
DNA. Plasmid DNA was collected by centrifugation at 10,000 x g for 15 min at 4°C.
The pellet was washed with 70% ethanol and resuspended in sterile deionized water.
The yield was 2 pg/ml bacterial culture.
(2) Wizard mini-preparation

To check for the presence ofthe appropriate plasmid within a given colony, a
small scale(<10 ml)plasmid DNA preparation was carried out using the Wizard
mini-preparation kit according to manufacturer's protocol. Four ml of a saturated

culture of bacteria were pelleted by centrifugation and resuspended in 200 pi of cell
suspension solution(50 mM Tris-HCl, pH 7.5, 10 mM EDTA and lOOpg/ml RNase
A). 200 pi of cell lysis solution (0.2 M NaOH,1% SDS)was added and mixed to
lyse the cells. 200 pi of neutralization solution (2.55 M potassium acetate, pH 4.8)

was added and mixed. The cell lysate was spun at 14,000x g for 5 min and the
supernatant was collected. One ml ofDNA purification resin was added to the
supernatant and loaded onto a mini-column by applying a vaecum. The column was

washed by the addition of2 ml column wash solution(200 mM NaCl,20 mM

Tris-HCl, pH 7.5, 5 mM EDTA)and the plasmid DNA was eluted with 50 pi of water
preheated to 65°C. The yield was about 1-2 pg DNA/ml bacterial culture.
(3) Qiagen maxi-preparation

For large amounts of plasmid DNA (lOOpg), which was used in plasmid
transfection experiments, the Qiagen plasmid preparation kit was employed according
to the manufacturer's protocol. Bacterial cells were collected by centrifuging 500 ml
of bacteria at 5,000 x g for 10 min at 4°C. The bacteria pellet was resuspended in
10 ml ofPI buffer(50mm Tris-HCl, pH 8.0, 10 mM EDTA and 100 pg/ml RNase A)
and 10 ml of freshly prepared P2 buffer(200 mM NaOH and 1% SDS), mixed and
the mixture was incubated at room temperature for 5 min. 10 ml ofice cold P3 buffer
(3.0 M potassium acetate, pH 5.5) was added, mixed and incubated on ice for 20 min.
The samples were centrifuged at 30,000 x g for 30 min at 4°C. The Qiagen-500 tip
was equilibrated with QBT buffer(750 mM NaCl,50 mM MOPS,pH 7.0, 15%
ethanol and 0.15% Triton X-100). The supernatant was loaded onto the Qiagen-tip

and the tip was washed twice with 30 ml of QC buffer(1.OM NaCl,50 mM MOPS,
pH7.0, 15% ethanol). The plasmid DNA was eluted from the Qiagene column with
15 ml of QF buffer (1.25 M NaCl, 50 mM Tris-HCl, pH 8.5, and 15% ethanol) and

precipitated with 0.7 volume ofisopropanol. The plasmid DNA pellet was collected
by centrifugation at 15,000 x g at 4°C for 30 min and washed twice with 70% ethanol.
The pellet was air dried for 5 min and redissolved in distilled water. The yield was

about 1 |J,g/ml bacterial culture and the DNA was stored at 4°C for immediate use or
stored at -85°C as aliquots for later use.
2. Sequencing

Sequencing was done with the commercial kit Sequenase 2.0(USB)which
employs the dideoxy- chain termination method (Sanger et ah, 1977) and a modified
bacteriophage T7 polymerase. The procedure used was as recommended by the
manufacturer for sequencing double-stranded DNA templates. Double-stranded
plasmid DNA was obtained using the mini-plasmid prep procedure described before.
To denature the DNA for sequencing, 10 pmoles of plasmid DNA in 18 pi of water
and 2 pi of freshly prepared 2 M NaOH were incubated for 5 minutes at room
temperature. The DNA was precipitated with 8 pi of5 M ammonium acetate pH 7.5
and 100 pi of cold absolute ethanol were added, mixed well and incubated at -20°C
for 30 minutes. The tube was centrifuged for 30 minutes at 10,000 x g at 4°C and the

supernatant was discarded. The pellet was rinsed with 500 pi of cold 80% ethanol by
inversion and centrifuged for 1 minute. All traces of ethanol were removed and the
pellet was stored at 4°C for up to one week. Denatured plasmid DNA(3 pmoles)in

6 pi of sterile water was armealed to 1 pmole of either the universal Ml3 primer or

the T7 primer by adding 2 pi ofreaction buffer and 2 pi of a 0.5 pmole/pl primer
solution, incubating the mixture at 37°C for 20 minutes and at room temperature for
an additional 15 minutes. During this incubation ,2.5 ml of each termination mix
(ddNTPs)were aliquoted to labeled microfiige tubes and placed on ice. To the

annealing reaction tube, the following were added in order: 2 |a.l of diluted (1:5)

labeling mix, l|il DTT,0.5 |il of[^^S] a-dATP (12.4 )iCi/^l) and 2 ^il of diluted
Sequenase (1:8). The labeling reaction was incubated for 2 minutes at room
temperature, and immediately 3.5 pi were transferred sequentially to each ofthe four

prewarmed termination tubes. Incubation was carried out for 5 minutes at 37°C and
4 pi of stop solution were sequentially added to the four reaction tubes. The reaction
mix was placed at -20°C until analyzed. The reaction products were analyzed on a
denaturing TBE,6M urea,8% polyacrylamide gel. The gel was run for 2.5 to 4 hours
at 50 constant watts. Gels were fixed in 1.5 L of 10% methanol, 10% acetic acid for

30 minutes and subsequently dried for 60 minutes at 80°C. Dried gels were exposed
to Fuji-X-Ray film without a screen for 1-5 days at room temperature.

3. Oligonucleotide probe labeling and purification
The Oligonucleotide probes were end-labeled with T4 kinase by the transfer of

y-[^^P]-phosphate to the 5-hydroxy group of the oligonucleotide probe as described
(Ausubel et al., 1994). The 10 pi labeling reaction mixture contained 50-100 ng of

oligonucleotides, Ipl 10 x TMDSE,200 pCi y-[^^P]-ATP and 1 unit ofT4
polynucleotide kinase. The reaction mixture was incubated at 37°C for 45 min and
the labeled oligonucleotide was purified with a Chroma spin-10 column (Clontech
inc., Palo Alto, CA). The Chroma spin-10 was first spun at 15,000 x g for 4 min and
the labeled reaction mixture was applied into the column. The column was spun for
4 min.

4. RNA Extraction

Total RNA was extracted from cells using a single step acid guanidinium-

thiocyanate phenol-chloroform method as described(Chomczynski et al., 1987)or a
new and substantially improved version ofthe single-step method, RNAzol
(Cinnai/Biotecx laboratories International Inc). For the Guanidinium-thiocyanate
phenol-chloroform method, the culture medium was removed from each 100 mm
dish of cultured prostate PC-3 cells and 1 ml of GIT solution was distributed over

each dish to lyse the cells. The cell extract was collected and stored at -80°C or used
to isolate total RNA immediately. For RNA extraction, O.I volume of2 M sodium

acetate(pH 4.0), I volume ofDEPC water-saturated phenol and 0.2 volume ofDEPC
water saturated-Chloroform/IAA (49:1) were added to the cell extracts sequentially

with complete mixing. The extraction mix was vortexed vigorously and incubated on
ice for 15 min and then centrifuged at 10,000 x g for 20 min at 4°C. The upper

aqueous layer containing the total RNA was transferred to a new tube and RNA was

precipitated by adding 1 volume ofisopropanol and storing at -20°C overnight. The
RNA was collected by centrifugation at 10,000 x g for 20 min at 4°C. The RNA

pellet was redissolved in 500 pi of GIT solution and reprecipitated by adding an equal
volume ofisopropanol and storing the solution at -20°C overnight. The RNA was

pelleted for 10 min at 14,000 x g at 4°C and washed twice(-20°C 80% ethanol). The
RNA pellet was dried by heating at 65°C for 5 min and dissolved in DEPC water.
The concentration and quality of the RNA was determined by reading the OD

at 260 nm and 280 nm,respectively. The isolated RNA was used for RT-PCR, and
QC-PCR.

For the RNA Trizol method, briefly, culture medium was aspirated, then 1 ml

RNA Trizol reagent was directly added into the flask, and cells homogenized with
repetitive pipetting. The lysis solution was transferred to a fresh Eppendorf tube and
stored for 5 min at room temperature, then 0.2 ml of chloroform was added and

centrifuged at maximum speed (Eppendorf centrifuge 5415) at 4°C for 15 min. The
aqueous phase was collected and mixed with 0.5 ml ofisopropanol. The RNA was
precipitated and dissolved in 10-15 |al of DEPC-treated water. The concentration of
RNA was determined by absorption at 260nm on the spectrophotometer. The yield of

total RNA is 3-7 |ig/10^ PC-3 cells.
5. Design, construction, and expression ofIGF-II ribozymes
(1)Design ofIGF-II ribozymes

The importance of hammerhead ribozymes is based on their ability to irreversibly
inactivate their targets and to turn-over in vitro (Haseloff et al., 1988), hammerhead
ribozymes work in cis (intramolecularly) in nature, and trans-hammerhead ribozymes

(intermolecularly), also can site-specifically cleave substrate RNA. It consists oftwo
parts, a catalytic core formed by 13 conserved nucleotides and a stem loop structure
(stem II)(Fig. 4). Two variable sequences, which together form the specific
sequence, located on each side ofthe catalytic core. The sequence allows the enzyme
to hybridize to a complementary target sequence present in the substrate RNA,

Ribozyme/substrate hybrid restores the 2 stems (I and III), which is the hammerhead

structure. After cleavage, the products can dissociate from the ribozyme, allowing
turn-over (Jeffries et al., 1989), so the ribozyme can bind to another substrate

molecule and cleave it as well. Hammerhead ribozymes were designed to target the
human IGF-II mRNA. Cleavage sites are based on the finding that sequences near
the translation initiation site are good targets for blockage ofIGF-II expression

(Christofori et al., 1994). The target RNAs for hammerhead ribozymes require the
sequence NUX in which N is any nucleotide, and X can be A, C, U. The optimum
length for ribozyme 2 arms(stem I and III) appears to be -14 bp by taking advantage
offacilitation by the endogenous cellular protein hnRNP Al. The two hammerhead

ribozyme sequences which we designed are follows: Ih and 2h (Fig. 14).
Complementary to the sequence around the translation initiation site of human prepro
IGF-II mRNA,nucleotide 16-30 and 16-46, respectively. The structure of single- and
double- ribozymes are shown in Fig. 15. For the control ribozymes, ribozyme
activity was lost in each ribozyme list above by introducing a point mutation of G to
A (Fig. 15). These ribozymes were subcloned into PTZU6+27(Fig. 16A), and
pcDNAS plasmids (Fig. 16B).

Single Ribozyme

5' ACCAGCAUCCUGAUGAGUCCGUGAGGACGAAACUUCCCC 3'

Double Ribozyme

5'AGAAGGUCUGAUAGUCCGUGAGGACGAAAGAAGCACCAGC
AUCCUGAUGAGUCCGUGAGGACGAAACUUCCC 3'
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(2)Subcloning of a IGF-II substrate

A template for human IGF-II RNA (-6 to +74)was prepared by PGR from the
full-length IGF-II cDNA (Bell et ah, 1994) and subcloned into pBluescript. The

primers for the PGR were: 1) 5'GGGAATTGGGAGAGGAATGGGAATGGG 3'
and 2) 5'GGGGATGGGGGGAGGGAGGAATGGAGGAGGA3',which contained
restriction enzyme cutting sites for BamHI and EcoRI, respectively. The PGR was

performed as followed: 95°G for 3 minutes, and then 30 cycle amplification at 95°G
for 1 min (denaturing), 55°G for 1 min (annealing), and 72°G for I min (extension).
After PGR,an aliquot ofthe PGR products was subjected to acrylamide gel
electrophoresis to check the quality ofPGR products. The PGR products were

cleaned up for subcloning, and digested with BamHI and EcoRI. At the same time,
a pBluescript KS plasmid was digested with BamHI and EcoRI. Restriction enzymedigested PGR products and the plasmid were isolated by low melting agarose gel
electrophoresis. The specific bands desired were cut out and incubated at 70°C for
5-15 min. For the ligation reaction, melted agarose containing insert and vector were
mixed in ligation buffer with T4 ligase, and incubated at 15°G overnight.

Transformation ofthe ligation mixture was achieved by electroporation. Briefly, 3 pi

ofthe ligation mixture were electroporated into E. coli XLl blue cells. After SOG
medium was added, the bacteria were incubated at 37°G for 1 hour to express

the antibiotic-gene, and plated on LB agar containing Ampicillin, X-gal, and IPTG at

37°G overnight. Plasmids were prepared from white colonies and their inserts

examined by BamHI/EcoRI double digestion and gel electrophoresis. Colonies
containing the right size insert were selected. To confirm the authenticity ofthe
IGF-II substrate sequence, plasmid DNAs were prepared and subjected to DNA
sequencing using Maxim-Gilbert USB methods.
(3) Construction ofIGF-II ribozymes

Template DNAs for ribozymes and mutant inactivated ribozymes were prepared
by PGR. The primers for the single head ribozyme (equal to ribozyme-lh,
mentioned above) were as follows:

1)5' ACG CGT CGA CCA GCA TCC T(A/G)A TGA GTC CGT GAG 3', 34 bases,
2)5' GCT CTA GAG CGG GGA AGT TTC GTC CTC ACG GAC TC 3', 35 bases,
which contains restriction enzyme Sail and Xbal sites respectively. The primers used
for the double head ribozymes(equal to ribozyme-2h) were: 1)5' ACG CGT CGA
GAG AAG GTC T(A/G)A TGA GTC CGT GAG GAC GAA AGA AGC ACC AGC
AT 3', 53 bases, 2)5'GCT CTA GAG CGG GAA GTT TCG TCC TCA CGG ACT
CAT(C/T)AG GAT GCT GGT GTT 3', 52 bases, which contained restriction
enzymes Sail and Xbal sites respectively. Note: in( / ), each nucleotide was 50%
incorporated in order to prepare both active and inactive ribozymes at the same time.
The template DNA for the ribozymes were prepared by PGR. The condition ofPGR
for signal head ribozyme was 5 cycles ofPGR,94°C for 1 min, 37°C for 1.5 min,
72°C for 1.5 min. The condition ofPGR for double head ribozyme was 5 cycles of
PGR,94°C for 1 min, 33°C for 1.5 min, and 72°C for 0.5 min. After the PGR,

the quality ofPCR products was examined by polyacrylamide gel electrophoresis.
The PCR products were cleaned up and digested with Sail and Xbal. At the same

time, a pTZU6+27 vector was digested with Sail and Xbal(pTZU6+27 contains the
human U6 promoter and pUC19 multiple cloning site. The plasmid containing the
ribozyme can be used for both in vitro transcription ofribozymes as well as

expression of the ribozymes in mammalian cells which use the Pol III RNA

polymerase). After digestion, a ligation reaction was carried out, and the ligation
products were electroporated into E. coli XL-1 blue cells, the bacteria were plated on
the LB agar which contains ampicillin, X-gal and IPTG. Plasmids were prepared
from white colonies and their inserts examined by Sall/Xbal digestion and gel

electrophoresis. Colonies containing the right size inserts were selected. To confirm
authenticity ofthe ribozymes, plasmid DNAs were prepared and subject to DNA

sequencing. Single ribozyme(R)and its mutant(M), and double ribozyme(RR), its
mutant(MM),and double ribozymes with one mutant(RM)and(MR)had been
isolated. Similarly, a pcDNA3 vector which has a CMV promoter was used as the
vector for single ribozyme and mutant ribozyme.

(4)Preparation ofIGF-II mRNA substrate by in vitro transcription

The plasmid which contains IGF-II substrate was linearied by BamHI digestion
and used as a template for in vitro transcription. Transcription reaction was carried at
37°C for 1 h in 40mM Tris-HCI buffer, pH 7.9 containing-0.2 pg DNA template.

0.5 unit/pl of T3 RNA polymerase, 20 mM MgCla, lOmM NaCl, lOmM DTT,

0.5 mM each of ATP,GXP,and UTP,O.OSmM CTP, lO^iCi of[a-^^P] CTP and
1 unit/|il of RNase. After transcription, the RNAs were treated with RNase-ffee
DNase I for 15 min, followed by gel purification in 6% denaturing polyacrylamide gel
for 1 hr at 200V. Before gel purification, a small aliquot ofRNAs was taken out for
calculating the specific activity. After gel electrophoresis, the gel was exposed to
a Kodak XRP film for 1 min and the film was developed. The appropriate region of
the gel containing the desired RNA band was cut out and crushed until it became fine

pieces. The lGF-11 substrate RNA was eluted in elution buffer overnight. The
aqueous phase was removed and mixed with phenol:chloroform:isoamyl alcohol to

extract the RNA. The substrate RNA was precipitated with ethanol, redissolved in
20 pi DEPC H2O and stored at -70°C.

(5)In vitro transcription oflGF-11 ribozymes
The plasmids containing ribozyme DNAs were linerarized by Xbal digestion and
used as templates for transcription oflGF-11 ribozymes as described for preparation of
the substrate RNA,except that a trace amount of the radioisotope was used, and also
that T7 RNA polymerase was used instead of T3 RNA polymerase. Transcription

reaction was carried at 37°C for 1 h in 40mM Tris-HCl buffer, pH 7.9 containing
-0.2 pg DNA template, 0.5 unit/pl of T7 RNA polymerase, 20 mM MgCl2, lOmM
NaCl, lOmM DTT,0.5 mM each of ATP, GTP, and UTP,0.05mM CTP, lOpCi of

[a-^^P] CTP and 1 unit/pl of RNase. After transcription, the RNAs were treated with
RNase-ffee DNase 1 for 15 min, followed by gel purification in 6% denaturing

polyacrylamide gel for 1 hr at 200V. Before gel purification, a small aliquot ofRNAs
was taken out for calculating the specific activity. After gel electrophoresis, the gel
was exposed to a Kodak XRP film for 1 min and the film was developed. The
appropriate region of the gel containing the desired RNA band was cut out and
crushed until it became fine pieces. The ribozyme RNA was eluted in elution buffer
overnight. The aqueous phase was removed and mixed with
phenol:chloroform:isoamyl alcohol(25:24:1) to extract the RNA. The substrate RNA
was precipitated with ethanol, redissolved in 20 pi DEPC H2O and stored at -70°C.
(6)Ribozyme cleavage assays

Ribozyme assays were performed as previously described (Bertrand et al., 1994;
Hertel et al., 1994). Briefly, ribozymes and substrate were heated independently for
1 min at 90°C in water. After cooling to 25°C, the reaction buffer was added to
a final concentration of lOmM MgCl2, 140 mM KCl, and 50 mM Tris-HCl, pH 7.5.

Ribozymes and substrate were then combined and incubated at 37°C. The reaction
was stopped by adding an equal volume of stop solution(0.5% of SDS/25mM EDTA)
and then with 100 pi of phenol. The aqueous phase was brought to lOOpl, extracted,

and precipitated with ethanol. The RNAs were analyzed by electrophoresis in
6% polyacrylamide/urea gels. Radioactive bands were visualized by autoradiography
and quantitated by a Phosphor Imager(Molecular Dynamics). Ribozyme/substrate
ratios and time course were determined.

6. Kinetic analysis of single and double IGF-II ribozymes

The single turnover experiments with ribozyme in excess over substrate were used
to determine the first-order rate constant for cleavage ofthe substrate (Hertel et al.,

1995). The initial cleavage velocities under single turnover conditions was
determined at a concentration of 1 nM substrate and several different ribozyme

concentrations over a 2 hour reaction time following initiation ofthe reaction. The

rate constants for the reaction(Kcat/Km) were determined from the slope of

semilogarithmic plots of the fraction of the ^^P-labeled substrate verus time
according to the equation log[A]=(-k/2.303)t.

The methods for the kinetic study were similar to the ribozyme cleavage reaction
as described above. First, both ribozymes and substrate were separately transcribed

by using T7 RNA polymerase and T3 RNA polymerase, respectively, in the presence

ofa-^^P CTP according to the methods described in the ribozyme cleavage reaction.

The transcripts were purified on a 6% polyacrylamide/8M urea gel. The ^^P-labeled
transcripts were detected by autoradiography. The transcripts were eluted from gel
areas showing the sizes expected, by extraction buffer. The RNAs were precipitated
at -20°C overnight or at -70°C for 20 min by adding 1 pi of 5 mg/ml tRNA and
2.5 vol. ethanol. The RNAs were recovered by centrifugation in a microcentriflige for

30 min at 4°C. Each RNA pellet was washed twice with 70% ethanol,2 mM EDTA
to remove traces of SDS, which would otherwise inhibit the ribozyme reaction. The

RNA pellets were dried in a speed-vac concentrator, the yields were quantified by

Cerenkov counting. The final concentrations were adjusted by dissolving the RNA
pellets in the appropriate volumes of TE buffer. Different combinations ofthe
substrate and ribozymes were heated at 90°C for 1 min, and then cooled to 25°C for
5 min. The cleavage buffer was added and incubated at 37°C for 1 hr. The ribozyme
reaction was stopped by adding 5 pi offormamide-dye mixture, and the products of

the ribozyme reaction were separated on a 6% polyacrylamide/8M urea gel. The
RNA products were quantified using phosphor imager.
7. Expression ofIGF-II ribozymes in cancer cells

The purpose of this aim was to examine whether the IGF-II ribozymes which
were active in vitro can work in cancer cells {in vivo). Unlike in vitro cleavage

reactions, when ribozymes are introduced into cells, additional factors which interfere
the ribozyme action may exist. These included i) co-localization ofribozymes with
the target RNAs,ii) ribozyme stability, iii) ribozyme expression level, iv) secondary

or tertiary structure of endogenous target RNA or ribozyme, as well as v)RNAbinding proteins.
(I) Selection of cell lines

Ribozyme activity was evaluated in cells that express IGF-II rtiRNA such as
human prostate cancer cell line PC-3 and human neuroblastoma SK-N-AS cell line.
SK-N-AS cells overexpressed IGF-II which is an autocrine growth factor for SK-NAS cells(El-Badry et al., 1989). PC-3 cells, epithelial cells derived from a human

prostate adenocarcinoma whose growth was androgen-independent(Kaighn et al..

1979), were shown to be capable of slow proliferation in serum-free medium and in
the absence of added growth factor for 7 days. These cells secrete insulin-like growth
factor-Il(IGF-II) but no detectable IGF-I. IGF-II, produced by these cells plays a role
in proliferation because cell growth could be inhibited dose dependently by up to 80%

in the presence of monoclonal antibodies directed against IGFs or the type 1IGF
receptor (Angelloz-Nicoud et ah, 1995; Jungwirth et ah, 1997).
(2)Determination of optimum concentrations of G418 for selection of
transformants

Since the amount of G418 required for obliteration of parental cells was likely to
be different among different cell types, the optimal concentration of G418 for
selection of transformed cells must be determined for each cell type. One ml of single

cell suspension at a concentration of 3.0 x 10^ cells/ml was plated into two 6-well
tissue-culture plates containing 3 ml RPMI 1640 medium with 10% FCS and
incubated at 37°C overnight. A series oftwo-fold dilutions of G418 from 75 pg/ml to

1.2 mg/ml in the medium were prepared. The medium was aspirated from the wells
and 4 ml of each dilution of G418-containing medium were placed in duplicate. The
medium without G418 was added to one set of wells. Plates were incubated at 37°C

for about 10 days until colonies formed. When colonies had grown to approximately
1-3 mm in diameter, the medium was aspirated, and the wells were rinsed with 2 ml
ofPBS. Colonies were incubated with 1 ml of0.5% methylene blue for 20 min.
rinsed with water to remove excess dye, and air-dried. The lowest G418

concentration resulting in 100% obliteration of cells was determined. For the PC-3
eells, the concentration was determined to be approximately 0.35 mg/ml. For the SK-

N-AS cells, the concentration was determined to be approximately 0.7 mg/ml.
(3) Cell culture and transfections

For pTZU6+27/Rz(Pol III promoter) and or pcDNA/Rz(Pol II promoter)
expression vectors, cells were transfected by calcium-phosphate precipitate method or
Electroporation method, respectively. The former vector was cotransfected with neo
vector whereas the later vector which contained neo gene was transfected by itself.
a) Calcium Phosphate

The method for calcium-phosphate precipitate was as follows(Sambrook et ah,
1980). Briefly, 24 hours before transfection, exponentially growing cells were

harvested by trypsinization, and replated into 90-mm tissue culture dishes. Ten ml of
RPMI 1640 medium with 10% PCS were added, and cells were incubated ovemight

at 37°C in a humidified incubator in an atmosphere Of5-7% CO2. To those cells,
were added 0.5 ml of 0.25 M CaCh containing 18 pg of superhelical plasmid
ribozyme DNA and 2 pg neo Vector DNA,and 0.5 ml of 2x BES-buffered saline.
The cells were incubated for 10-20 minutes at room temperature. RPMI 1640

medium with 10% PCS were added dropwisely to the cells in the dishes, the dishes
were swirled gently, and were incubated for 15-24 h at 37°C in a humidified

incubator in an atmosphere of3% CO2. The calcium phosphate-DNA complex
formed slowly in the medium under conditions oflow pH and precipitateed gradually

onto the cells during the incubation in an atmosphere containing low concentrations
of CO2. The medium was removed by aspiration, and cells were rinsed twice with
medium. Ten ml of fresh medium were added, and cells were incubated for 24 h at

37°C in a humidified incubator in an atmosphere of5% CO2. Following 18-24 h
incubation in nonselective medium to allow expression ofthe transferred genes to
occur, the cells were trypsinized and replated in medium containing the appropriate
concentration of G418. The medium was changed every 2-4 days for 2-3 weeks to

remove the debris of dead cells and to allow colonies of G418-resistant cells to grow.

Individual G418-resistant colonies were picked up, grown, and screened for
expression of the ribozymes. The ribozyme-expressing cells were analyzed for IGF-II
mRNA and protein levels, cell growth, morphological changes, etc.
b) Electroporation

Cells were grown to 70% confluence, trypsinized in the minimum time possible
(1-3 minutes) centrifuged in the table-top centrifuge, and resuspended in HEBS buffer

at a cell density of 1-10 x 10^ cells per ml. This suspension was preincubated with 5
to 20 pg of DNA on ice for 10 minutes with mixing, transferred to cuvette and

immediately pulsed with a range of settings. A 2 mm gap chamber was used in a

BTX electroporator(San Diego, CA). The settings were first adjusted to include
parameters used to successfully transfect SK neuroblastoma cells. These were T=
500 V, Capacitance=800-900 pF, Resistance=R4(72 ohm). Charging voltage=
350 Volts, Electric Field Strength (EFS)=1.0 kV/cm, and designated pulsed length

=0.2-10 mSec. The sample volume was 400 pi in all cases. After pulsing, the cells
were left at room temperature for 10 minutes, transferred back into the petri dish, and
selected using G418 for at least 1 month.

(4) Expression ofthe hammerhead ribozyme in mammalian cells
To detect ribozyme expression in transfected G418-resistant clones, RT-PCR was
used (Funato et al., 1994). For pTZU6+27 clones, a set of primers for detection of
ribozyme was prepared. One primer(Rz5') contains a sequence corresponding to the

junction between U6 promoter and the ribozyme. The other primer(Rz3') contains a

transcription termination sequence. The sequences ofthem are as follows: 5'primer,
5' TCG CTT CGG GAG GAG GTG GAG,3'primer, 5'GGG AAG TTT GGT GGT
GAG GGA. For pcDNA3 clones, a set of primers are as follows: 5'primer, 5'GGG
AGT GGT TAG TGG GTT ATG GA,3'primer, GGA GAG TGG GAG TGG GAG

GTT G. RT reaction products, equivalent to 200 ng oftotal RNA from each clone,
were processed through 30 cycles ofPGR with denaturation at 94°G for 1 min,
annealing at 47°G for 2 min, synthesis at 72°G for 3 min,in a final volume of20 pi
for pTZU6+27 clones and through 30 cycles ofPGR with denaturation at 94°C for

30 second, annealing at 67°G for 1 min, synthesis at 72°G for 1 min,in a final volume

of20 pi for pGDNA3 clones. Half ofthe reaction product was analyzed in a 2%
agarose gel and blotted to a nylon membrane. Blots were hybridized to a specific

^^P-labeled oligonucleotide probe (ribozyme catalytic domain). The sequence ofthe

probe was as follows, 5'ACC AGC ATC CTG ATG AGT. The ribozymes were
visualized by autoradiography and quantified by Phosphor Imager.
8.

Effect ofIGF-II ribozyme expression on cancer cell lines

(1) Quantitation of Ribozyme target IGF-II abundance by QC-PCR
A competitive PGR was developed for quantitative analysis ofribozyme IGF-II
RNA,this method showed very good specificity and sensitivity, allowing quantitation

in a large linear range.(Payan et al., 1997; Revillion et al., 1997; Fasco, 1997;
Lewohl et al., 1997).

a) Construction of QC-RTPCR internal control (competitor) plasmids
pBluescript KS/IGFII, pBluescript KS(-i-)(Stratagene, San Diego)containing
approximately 1 kb EcoRI fragment encoding the human precusor IGF-II(911 to
2067 nt.. Dull et al., 1984), was used to generate a new plasmid which encodes a

competitor IGF-II sequence. Construction ofthe plasmid encoding the competitor
IGF-II is schematically presented in Fig. 20. pBluescript KS/IGFII was digested by
EcoRI and the 1.0 kb EcoRI fragment was ligated into the EcoRI-digested pBluescript
SK vector. E. coli was transformed with the ligated plasmids and clones which
contained the insert in the opposite direction to the original IGF-II clone were

selected by restriction enzyme analysis using Xhol and a combination of Xhol and
PvuII. Since the 1.0 kb EcoRI/EcoRI insert as well as multi-cloning sites contained

unique Sail and Xhol sites, the pBluescript SK/opIGFII plasmid was digested by
Xhol, from which the larger Xhol/Xhol fragment was separated from the small

Xhol/Xhol fragment. Self ligation ofthe larger Xhol fragment resulted in

pBluescriptSK/IGFIIS encoding the shortened IGF-II sequence which had a unique
Sail site. This was confirmed by restriction enzyme analysis. While pBluescript
SK/IGFIIS yielded one linear band with Sail digestion and three bands of 1506,683,

353 bp with PvuII digestion, Xhol and Sail digestion resulted in only a 174 bp hand.
This plasmid was digested by Sail, to which a 1 lObp Sall-Sall fragment was inserted.
The new plasmid, pBluescript SK/IGFIIS/C, showed restriction enzyme maps of
1506,683, and 463 bp whereas the original pBluescriptSK/IGFIIS showed restriction
enzyme maps of 1506,683, and 353 hp with PvuII digestion,
b)Sjmthesis of QC-RTPCR internal control(competitor) RNA
The pBluescript SK/IGFIIS/C was linearized by Xhol digestion, and used as the

templates for in vitro transcription. Transcription reaction was carried out at 37°C for
I h in 40 mM Tris-HCl buffer, pH 7.9, containing -0.2 pg DNA template, 0.5 unit/pl

of T3 RNA polymerase, 20 mM MgCl2, 10 mM NaCl, 10 mM DTT,0.5 mM each of
ATP, GTP,UTP,CTP and 1 unit/pl of RNasin. After transcription, the RNAs were
treated with RNase-free DNase I for 15 min. The RNA mix then was stopped by

adding 115 pi of RNase-free dH20 and 15 pi of Ammonium Acetate Stop Solution.
The reaction mix was then extracted with an equal volume of water- or buffer-

saturated phenol/chloroform, and once with an equal volume of chloroform, the RNA

was precipitated by adding 1 volume ofisopropyl alcohol at -20°C for at least 15 min.

centrifuged for 15 min at maximum speed, the aqueous phase was removed and the
RNA was resuspended in RNase-ffee dH20 and stored at -70°C.
c) Quantitative analysis of control(competitor) RNA
A series of RT-PCR were performed at 47°C for 30 min by using 50ng, 5ng,
O.Sng, O.OSng, O.OOSng control (competitor) RNA and 10 pmol ofthe 3' primer,
IGFII3', the sequence of it is as follows, 5' GTA TCT GGG GAA GTT GTC CGG

AAG CAC GGT C,in 50 mM Tris-HCl, pH 7.5, containing 10 mM DTT,75 mM
KCl, 3 mM MgCl2, 1 mM of each deoxynucleoside triphosphate(dNTP),800 u of
superscript II reverse transcriptase(RT), and 20 u of human placental ribonuclease
inhibitor. To inactivate the RT,the reaction mixture was incubated at 65°C for

10 min. One quarter ofthe cDNA obtained from the RT reaction was incubated in
presence of2 u of Taq polymerase in 0.25 mM of each dNTPs, 10 pmol of 5' end P
y-ATP labeled primers, IGFII 5' primer, the sequence of it is as follows, 5'CCA GCA
CCA ATG GGA ATC CCA ATG GGG AAG,and 10 pmol 3' end primers, 50 mM

KCl, 1.5 mM MgCl2, 10 mM Tris-HCl, pH 7.5, and 0.1% Triton-X-100. Reaction
mixtures were overlaid with mineral oil and placed in a DNA thermal cycler for
25 cycles(94°C for 1 minute,68°C for 30 Seconds, 72°C for 1 minutes). The PCR-

amplified products were analyzed by electrophoresis in a 3.5% acrylamide gel in TBE
Buffer. After the electrophoresis, the gel was transferred to a Whatman membrane,
then the membrane was dried and exposed to film. The PCR products were

visualized by autoradiography and quantitated using a Phosphor Imager. An internal
control titration curve was plotted as total RNA amount vs band intensity,
d)Analysis of control(competitor)RNA vs PCR cycles
RT-PCR was performed by using 0.5 ng internal control competitor RNA as
described as above under 16, 20, 24, 28, 32 cycles. A 10 pi reaction product was
removed from the reaction and analyzed by gel electrophoresis, and the PCR products
were visualized by autoradiography and quantitated using a Phosphor Imager. The
cycle curve was plotted as cycle numbers vs band intensity.
e) Quantitation of IGF-II abundance in ribozyme expressing clones

RT-PCR was performed at 47°C for 30 min by mixing 4 pg oftotal RNA from

the transformants (total RNA amount was modified by ribosomal RNA)with a certain
amount ofinternal control competitor RNA and 10 pmol of the 3' primer(same as
above), in 50 mM Tris-HCl, pH 7.5, containing 10 mM DTT,75 mM KCl, 3 mM
MgCb, 1 mM of each deoxynucleoside triphosphate(dNTP), 800 u of superscript II
reverse transcriptase(RT), and 20 u of human placental ribonuclease inhibitor. To
inactivate the RT,the reaction mixture is incubated at 65°C for 10 min. One quarter
ofthe cDNA obtained from the RT reaction was incubated in presence of2 u of Taq

polymerase in 0.25 mM of each dNTPs, 10 pmol of 5' end ^^P y-ATP labeled primers
and 10 pmol 3' end primers, 50 mM KCl, 1.5 mM MgCb, 10 mM Tris-HCl, pH 7.5,

and 0.1% Triton-X-100. Reaction mixtures were overlaid with mineral oil and placed
in a DNA thermal cycler for 25 cycles(94°C for 1 minute, 68°C for 30 Seconds, 72°C

for 1 minutes). The PCR-amplified products were analyzed by electrophoresis in a
3.5% acrylamide gel in TBE Buffer. After electrophoresis, the gel was transfered to
a Whatman membrane,then the membrane was dried and exposed to film. The PCR
products were visualized by autoradiography and quantitated by using a Phosphor
Imager.

(2) Measurements ofIGF-II protein level in PC-3 transfectants
The level ofIGF-II protein secreted into conditioned medium and in cells were

analyzed by RIA assay using IGF-II mAb. For each clone, a duplicate of 10^ cells
were seeded in T-25 flask and incubated at 37°C overnight. The next day. The
medium was aspirated and the cells were washed three times using I x PBS,then the
serum free medium was added and the cells were incubated for 2 more days without
changing the medium. The medium were collected and analyzed by RIA assay using
IGF-II mAb(Mohan et ah, 1990). This part of study was done in collaboration with
Dr. Mohan's group, Loma Linda University VA Hospital.
(3)Fffect ofribozyme expression on PC-3 cell growth
a) MTT Assay

Growth curve was done by MTT Assay, the cleavage and conversion ofthe

soluble yellow dye to the insoluble purple formazan has been used to develop an

assay system alternative to the conventional ^H-thymidine uptake and other assays for
measurement of cell proliferation. Active mitochondrial dehydrogenated from living
cells will cause this conversion. Dead cells do not cause this change, this has been

used measuring cell cytotoxicity and cell number. PC-3 parental cells, vector clone
cells, and ribozyme clone cells were seeded in 96 wells at 1x1

in triplicate and

cultured for 4 days. Each day, 20 pi MTT(5mg/ml)was added to a set of cells, and
the cells were continued to be incubated at 37°C for 4 hours, and the medium was

then removed and replaced with 100 pi isopropyl alcohol supplemented with 0.05 N
HCL. The samples were read at 540nm. The growth curve was plotted as OD vs

b)Time-lapse microscopy

Cell division ofPC-3 cells, vector-transfected cells, and R-expressing PC-3 cells

was measured revealing doubling time. Approximately 10^ Cells of each clone was
seeded in a T-25 flask and incubated at 37°C overnight, and then placed in a special
incubator under microscopy. A good microscopy view ofisolated cells was selected
and the cells were continued to incubated for at least four days, cells' doubling time

was recorded. For each clone, at least eight individual cells' doubling time was
observed and the average was taken as the doubling time for this clone.
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RNA substrate was cleaved into two fragments of213 bases and 944 bases by single
ribozyme (R), while double ribozyme(RR)cleaved the substrate into 3 fragments of

213 bases, 928 bases and a small fragment of 16 bases(which was not seen on this
3% acrylamide gel) after a 16-hr digestion. The time course experiments showed that
double- ribozyme(RR)cleaved the human prepro IGF-II RNA in a time-dependent
maimer, while the single ribozyme(R)showed a less cleavage activity than RR
(Fig. 18).
2. Kinetic analysis of single and double IGF-II ribozymes
The single turnover experiments with ribozyme in excess over substrate were used
to determine the first-order rate constant for cleavage ofthe substrate (Hertel et al.,

1995). The kinetic analysis of both single R and double RR ribozymes is shown in
Fig. 19 and summarized in Table 4; Kcat/Km for single ribozyme R was 1546

while Kcat/Km for double ribozyme RR was 4772 M"^ S"\ The results clearly show
that the double ribozyme is more efficient than the single ribozyme in in vitro
experiments.

B. Quantitation of IGF-II mRNA by QC-RTPCR
1. Synthesis ofinternal control IGF-II

Internal control (competitor) plasmid was constructed according to the method

described above. Construction ofthe plasmid is schematically presented in Fig. 20.
Internal control(competitor) RNA was synthesized using T3 RNA polymerase.
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Table 4. Kinetics of single- and double-nbozymes.

Keat/Km,IVT^ S"'
R

RR

Expenment 1

1870

5840

Expenment 2

965

3704

Expenment 3

1803

Average

1546 + 411

4772

2. Quantitative IGF-II mRNA analysis
A serial dilution ofthe internal control RNA was reverse-transcribed, and then

PGR product was amplified using primers specific to IGF-II (Fig. 20). The internal

control titration curve as shown in Fig. 21A revealed good linearity within this range
ofinternal control RNA. A 0.5 ng internal control(competitor) RNA was reverse-

transcribed, then subjected to different PGR cycles as indicated in Fig. 21 B. The
PGR product and cycle number were linear up to 28 cycles.
C. IGF-II ribozyme action in cancer cells

1. Expression ofIGF-II ribozyme in human prostate cancer cells under the control of
Pol III promoter
(1)Ribozyme expression in PG-3 cell transfectants

Genecitin (G4I8)-resistant stable clones were screened by RT-PGR to check

whether ribozyme was expressed. From transfection with pTZU6-i-27 vector, 4 single
ribozyme(R)clones, 2 double ribozyme(RR)clones, and 2 mutant ribozyme(M)
clones were isolated. Expression ofribozyme in these clones was further confirmed

by Southern hybridization using a ribozyme-specific probe as shown in Fig. 22A,B.
(2)Effect on IGF-II mRNA levels

The flow chart of quantitative RT-PGR is shown in Fig. 23. The levels ofIGF-II
mRNA in ribozyme and mutant expressing PG-3 clones were determined by QG-RT-
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PCR. As shown in Fig. 22C,in each lane, two bands are seen in each lane, the upper

band (internal control) with ~ 400 bases and the lower band (endogenous IGF-II) with

~300 bases, the sizes of which were consistent with the predicted size. The relative
IGF-II mRNA expression levels in different clones were expressed as the ratio of

endogenous IGF-II/intemal control. The results shown in Fig. 22D elearly
demonstrate that both single and double ribozymes significantly reduce the IGF-II

mRNA levels while mutant rihozyme had little effect on IGF-II mRNA expression
compared to the PC-3 parental cells.

(3)Effect ofIGF-II rihozyme expression on cell growth

.The results of pTZU6+27 PC-3 clones are shown in Table 5. While cell numbers
of parental PC-3 cells or M-expressing cells increased after 2 days in serum fi^ee
medium, cell numbers of R- or RR- expressing cells(pTZU6+27)decreased, which
indicates that rihozyme expression may have caused cell death.
2. Expression ofIGF-II rihozyme in human prostate cancer cells under the control of
Pol II promoter
(1) Rihozyme expression in PC-3 cell transfectants

Genecitin (G418)-resistant stable clones were screened by RT-PCR to eheck

whether the rihozyme was expressed. From transfection experiments with pcDNA3
vectors, eleven G418-resistant clones were isolated. Among those eleven clones, four
clones expressed single rihozyme(R)as shown in RT-PCR Fig. 24A.

Table 5. Effect of ribozyme(pTZU6+27)expression on PC-3 cell growth.
Relative cell growth after 2 days in SFM

Mean ± SE
parental PC-3

1.23 ± 0.02(n=2)
R-expressing PC-3

0.58 ±0.13(n=5)
RR-expressing PC-3

0.4(n=l)
M-expressing PC-3

1.61 ±0.33(n-2)

(2)Effect ofIGF-II ribozyme on IGF-II mRNA levels

The levels ofIGF-II mRNA in pcDNAS stable ribozyme and vector PC-3 clones
were determined by QC-RT-PCR. As shown in Fig. 24B,in each lane, there are two
bands, the upper band (internal control) with ~ 400 bases and the lower band
(endogenous IGF-II) with ~300 bases, the sizes of which were consistent with the
predicted size. The relative IGF-II mRNA expression levels in different clones was
expressed as the ratio of endogenous IGF-II/intemal control. The relative IGF-II
mRNA levels in different R-expressing clones were reduced as compared to the
vector only clones and the PC-3 parental cells (Fig. 24B).
(3) Effect ofIGF-II ribozyme on IGF-II protein levels

For the pcDNA3 ribozyme clones, the level ofIGF-II protein secreted into
conditioned medium was analyzed by radioimmunoassay. This was done in
collaboration with Dr. Mohan's group, Loma Linda University VA Hospital(Mohan
et al., 1990). The IGF-II protein levels among different clones are shown in Fig. 24C.
Ribozyme expressing PC-3 clones showed relatively lower IGF-II protein levels.
consistent with the lower IGF-II mRNA levels.
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(4)Effect ofIGF-II ribozyme on cell growth
a) MTT assay

Effect ofribozyme expression(pcDNA3 vector) on PC-3 cell growth was measured

by MTT assay, the result is shown in Fig 25. Ribozyme-expressing transfectants
showed a significant decline in cell growth compared to the parental PC-3 cells, and

vector expressing transfectants both in serum-ffee medium and 2% FCS medium.
b)Time-lapse microscopy.

Effect ofribozyme expression on doubling time ofPC-3 cell grown in the

presence of 10% FCS is shown as Table. 6. Analysis of cell division of parental PC3 cells, vector-transfected cells, and R-expressing PC-3 cells(R4,R6, and R39)
revealed doubling times(mean±SEM)of 28.3 ± 0.39(n==8), 32.3 ±1.0(n=3), 37 ± 1.1
(n=6), 38.6 ±2.3 (n=5), and 42.5 ±2.8(n=2) hr, respectively. Compared to the

parental PC-3 cell, rihozyme-expressing clones showed a significantly prolonged
doubling time while the doubling time of vector-transfected PC-3 cells was not
significantly different from that ofthe parental cells (Table 6).

%

Table 6. Effect of ribozyme expression(pcDNA3)on PC-3 cell growth as measured
by time lapsed microscopy
R-expressing transfectants
R4

Doubling time ± SEM (hr)

R39

37 ± 1.1 38.6±2.3 42.5+2.8

131

[PC-3: 28.3 ± 0.39 hr]

R6

P<0.01

136
P<0.001

150
P<0.001

Vector

transfectant

32.3 + 1.0

114
P>0.05

D. Summary
In summary ,this study demonstrated:

1) Single (R)- and double (RR)-ribozymes were catalytically active in vitro. RR was
more active than R in vitro.

2) Both R and RR ribozymes similarly suppressed IGF-II mRNA levels in PC-3 cells
(~40%)as compared to the level in parental PC-3 cells.
3) Pol II and Pol III promoter-driven ribozymes similarly suppressed IGF-II mRNA
levels.

4) Suppression ofIGF-II mRNA levels are correlated with suppression ofIGF-II
protein levels.
5) R-(or RR-)expressing cells showed reduced cell growth and prolonged doubling
time as compared to those of parental or M-expressing cells.

V. GENERAL DISCUSSION

A. IGF-II expression in human tumor tissues

In our published studies included in Chapter II, we used in situ hybridization and
immunohistochemistry methods to determine IGF-II expression in tumor tissues in
vivo. The results showed that IGF-II expression is confined to epithelial cells and not
stromal cells, implicating that cancer cell growth may be regulated by IGF-II in an
autocrine manner, and also provided the basis that IGF-II is a pertinent target for
ribozyme manipulation.

It should be noted, however, that we also observed a peculiar focal expression as
well as an elevated expression ofIGF-II in benign epithelium ofthe prostate. We
must consider a possible contribution of stromally expressed IGF-II to the

development of prostate cancer and BPH. With respect to IGF-I, recent tissue
recombinant studies by Cunha's group (1998)demonstrated that the IGF-I pathway

plays a critical role in prostatic development. In their studies, local IGF-I expression
appears to play the role. In contrast, elevated IGF-I levels in plasma(systemic) are
associated with a higher risk of prostate cancer(Chan et al., 1998). The roles ofIGFs
in prostate physiology and cancer remain important areas for future investigation.
B. IGF-II ribozyme action

Ribozymes have been used as a molecular tool to inactivate gene expression in
some studies(Kashani-Sabet et al., 1992; Koizumi et al., 1992; Dorai et ah, 1997).

A couple of studies using ribozymes to modulate oncogene expression have been
reported previously. These included a ribozyme specifically targeting a mutant

oneogene codon in which the mutation was suitable for ribozyme activity (KashaniSabet et ah, 1992). Another study showed that an anti-p53 ribozyme designed to
eleave the p53 pre-messenger RNA(mRNA)can efficiently reduee the level of
endogenous mutant p53 mRNA(De Weiet ah, 1995). Our studies demonstrated that

IGF-II ribozymes are catalytically-active in vitro, and capable ofredueing IGF-II
mRNA and protein levels in prostate caneer cell lines.
There are several good reviews describing the optimal design for ribozymes

(Deshler et ah, 1992; Castanotto et ah,1995). The maximum optimal design is,
however, achieved basically by a trial and error process. A computer program may

provide some structural information on secondary or tertiary structures of the
substrate which might impair ribozyme activity (Zuker et ah, 1981; Sun et ah, 1994).
Recently, Pachuk et ah (1994) developed a potential novel design, which used a

ribozyme anchor to overcome an obstruction caused by seeondary strueture around a

cleavage site. In our study, we have used a hammerhead ribozyme motif because of
its small size and ease of manipulation. The IGF-II ribozyme cleavage site near the
translation initiation codon was chosen based on the results of antisense

oligonucleotide experiments which were performed in Dr. Fujita-Yamaguchi's
laboratory (unpublished).

Single- and double-hammerhead ribozymes were analyzed in vitro and cloned into

the pTZU6+27 or pCDNA vector. The in vitro result showed that the double
ribozyme is more efficient than the single ribozyme as judged by single turnover
kinetics as well as cleavage reactions using the prepro IGF-II mRNA as a substrate.
This is probably because the double ribozyme has two cleavage domains while the
single-headed ribozyme has only one cleavage domain.
Ribozyme gene delivery was achieved by two methods, calcium phosphate or
electroporation. Both mothods seemed to work equally well in this study.
Establishment of quantitative assays for the target RNA is necessary for the detection
ofribozyme cleavge reactions in vivo (in cell lines). Previous studies used Northern
blot analysis, RNase protection assays, and RT-PCR(Funato et al., 1994; Efrat et al.,
1994). In our study, the QC-PCR method was used because it is very sensitive,

specific, and quantitative (Beaudry et al., 1995). QC-PCR uses one pair of primers
for both endogenous and competitor RNAs in contrast to most of the RT-PCR

methods which use two pairs of primers. The competitor IGF-II RNA shares the
same sequences for primer binding as the target endogenous IGF-II mRNA,but
contains an additional 110 base-long insert which will give a PGR product larger than
the PCR product generated from the target endogenous IGF-II mRNA. This 110 base

difference in size is sufficient for easy separation ofthe PCR products on denaturing
polyacrylamide gels and for quantitation ofthe radioactive bands with a Phosphor
Imager.

We must acknowledge that although in vitro studies ofribozymes are essential
steps for learning their catalytic mechanisms, in vitro studies cannot be used to

predict the efficiency ofthe ribozymes when expressed in cells. For example, Domi
et al.,(1996) designed a small anti-HIV hammerhead ribozyme, the ribozyme was
active in the cell, but inactive in vitro. Interestingly, in our study, single- and doubleribozymes showed almost the same level of efficacy in reduction ofIGF-II mRNA in
cells. This observation can be explained in the following ways: 1)due to secondary

or tertiary structure, interaction ofIGF-II mRNA with the double-headed ribozyme
makes one ofthe cleavage domains unable to anneal with the substrate, thus there is
no cleavage reaction for that domain; 2) within the cell, mRNA is stabilized by the
structure of 5' Cap and 3' poly A tails, if one cleavage domain anneals with the

substrate, and subsequently cleaves the substrate mRNA,then the broken IGF-II
mRNA is easily degraded by a variety ofribonucleases within the cell; 3) the

ribozyme cell clones are those selected by the cell which is able to moderately reduce
IGF-II to a point which does not cause cell death. The results tell us that, compared
to in vitro experiments, ribozyme activity is likely to be altered in the cellular
environment.

Other factors which may interfere with ribozyme action need to be considered.

These factors include ribozyme expression level, co-loealization ofribozyme with the
targets, location ofthe ribozyme gene relative to the target gene in the host genome,
sites at which the ribozyme functions, secondary structure of the target RNA or

ribozymes, cofactors or inhibitors like proteins, Mg^^ concentration, pH, etc. Due to
the complexity of eukaryotic gene expression, and also these multiple factors, we

must acknowledge that this technology is not straightforward as simply expressing a
complementary sequence in vivo. If ribozyme expression is not highly efficient, the
level ofribozymes may be too low to cleave the target RNA. Even though ribozymes
are efficiently expressed, if ribozymes are not in the same cell compartment with the
target RNA,ribozyme activity would be dramatically decreased. One common
observation in ribozyme/antisense studies is the extreme variation in the effectiveness
ofribozymes produced from the same gene located at different chromosomal
positions(Kim et al., 1985; Van der krol et al., 1988; Cannon et ah, 1990). In

general, the end result is that only a small proportion oftransgenic organisms
transformed with any one DNA construct show an effect. The effectiveness ofthe
antisense/ribozyme produced appears to be unrelated to either the number of
antisense/ribozyme genes or the steady-state levels ofthe antisense/ribozyme RNA.
In addition, unlike most situations, there are systems in which an antisense RNA
functions effectively when expressed at a lower steady-state level than the target

mRNA (Nishikura et al., 1987; Sheehy et al., 1988). In contrast, there are examples
in which massive overexpression of antisense/ribozymes, relative to the target
mRNA,have failed to down-regulate expression of the target gene (Kerr et al., 1988).

One explanation given is the influence of position effect on the expression of
integrated antisense/ribozyme genes. Amdt et al.(1997) gave a more complex
explanation, it is possible that the location ofthe antisense/ribozyme gene relative to
the target gene may be even more important. They defined this as location effect.

which refers to the influence ofthe antisense/ribozjmie gene position relative to the

target gene on the extent ofinhibition mediated by the expressed antisense/ribozyme.
The extent ofthe observed location effect can be adjusted by the influence ofclassical

position effects, wherein the flanking chromosomal DNA at the site ofintegration of
the antisense/ribozyme gene can affect the level and timing of expression of the

antisense/ribozyme. It may he that integration of antisense/ribozyme genes into
different sites in transgenic mammalian cell lines leads to different local

concentrations of antisense/ribozymes at the position ofthe target gene or in the

vicinity ofthe target mRNA. Within this scenario, there is no need for a correlation
between the concentration of antisense RNA and the extent of inhibition.

The secondary structure ofthe target RNA or ribozymes is also very important.
Since ribozymes cleave the target RNA by first complementary binding to the target
RNA,if the secondary structure of target RNA or ribozymes interfere with the

binding ofribozyme and target, ribozyme activity will be reduced. Also, proteins
may bind to portions ofthe RNA substrate or to the ribozyme itself, and may
facilitate or interfere with the catalysis. A limited number of reports demonstrated an

enhancement ofribozyme cleavage reactions by RNA-binding proteins like hnRNP

A1 or the capsid protein NC7 of HIV-1 (Bertrand et al., 1994; Tsuchihashi et al.,
1993; Herschlag et al., 1994). In our study, pTZU6+27 vector and pcDNA were used,

pTZU6+27 has an advantage for directing the expression of short, defined transcripts
in high copy number under control ofRNA polymerase 111 promoter. These RNAs

are relatively stable, both in nucleus and cytoplasm, but mainly in the nucleus(Good
et al., 1997; Bertrand et al, 1997; Michienzi et al., 1996;). pcDNA vector(CMV

promoter)can be ubiquitously expressed under the control ofRNA polymerase II.
The ribozyme transcript will be mainly expressed in cytoplasm. Both Pol II and Pol
III driven vectors have worked successfully in our ribozyme studies. Pol II
promoters, including viral promoters, which are used naturally for mRNA synthesis,
can allow tissue-specific expression ofribozymes. Despite differences in the amount
ofribozyme transcripts obtained fi-om different promoters, their ability to confer
resistance to HIV-1 replication is similar(Zhou et al., 1996). A disadvantage ofPol II
promoters is their requirement for long coding sequences, so that the ribozyme
sequence may be placed in long RNA molecules. This can interfere with ribozyme
conformation. In contrast, Pol III promoters, which naturally drive tRNA and snRNA
synthesis, are good for very-high-level, non-tissue-specific expression of short RNA.
For example, Thompson et al.(1995) used a tRNA-based RNA polymerase III
promoter driven ribozyme, and found that high accumulation ofrecombinant pol III
ribozyme transcripts was observed in all cell lines tested, and that the ribozyme

activity was readily detectable in total RNA extracted from stably transduced human
T cell lines. Michienzi et al.(1996)used U1 small nuclear RNA chimeric ribozymes
with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus,
and showed that this construct caused more efficient reduction of Rev pre-mRNA in
vivo. Kawasaki et al.(1996)reported that by using a Pol III driven vector, the

adenoviral-El A-associated 300-kDa-protein expression in HeLa eells was inhibited.
In our study, both Pol II and Pol III driven vectors similarly suppressed IGF-II mRNA

levels in PC-3 cells. Suppression ofIGF-II mRNA levels are correlated with reduced

IGF-II protein levels. Ribozyme expressing eells showed reduced cell growth and
prolonged doubling time as compared to those of parental or M-expressing cells.
These results supported our hypothesis that prostate cancer cell growth is regulated by
IGF-II in an autocrine manner.

C. Observation

One interesting observation in our study was that when I stably transfeeted SK-NAS eells with pTZU6+27/Rz, first, some clones grew. These clones were picked up
and placed in 96 well plates, and then in T-25 flasks. These clones, however, never

continued growing, but eventually died off. In contrast, SK-N-AS cells transfeeted

with pTZU6+27/mutant Rz could continue to grow even into T-75 flasks. This
suggests that since SK-N-AS cells are more dependent on IGF-II for their growth than
PC-3 cells, IGF-II ribozyme-expressing clones could not survive. An experiment was
carried out using pcDNA vectors encoding IGF-II ribozyme(R)and mutant ribozyme
(M). SK-N-AS cells were stably transfeeted with these vectors. After one month

culture in selection medium containing G4I8,1 found far less R-expressing clones
than M-expressing clones. This supports the fact that IGF-II plays an important role
in SK-N-AS cells and suggests that an alternative strategy for designing an IGF-II
ribozyme is necessary, that is, using an inducible vector, so that we can turn off

ribozyme expression first to get stable clones and then turn on ribozyme expression to
see the effect of ribozyme on the growth of cancer cells.

D. Mechanisms by which suppression of IGF-II RNA and protein affects cancer
cell growth

In this study, IGF-II ribozymes targeted to the IGF-II mRNA were evaluated in
prostate cancer PC-3 cell line. The result showed that both IGF-II mRNA and IGF-II

protein levels were decreased, and that prostate cancer cell growth was delayed. This
clearly demonstrated that IGF-II was important in supporting PC-3 cell growth. The
potential mechanisms by which suppression ofIGF-II RNA and protein affects cancer
cell growth are presented below:

1. Mitogenic response in prostate cancer cells is mainly via IGF-II binding to IGF-I
receptor. The IGF-I receptor mediates mitogenic and antiapoptotic effects on normal
and transffomed prostate eptithelial cells(Cohen et al., 1991; Rajah et al., 1997). By
decreasing IGF-II levels, the mitogenic signal is decreased and more prostate cancer
cells go through programmed cell death, apoptosis.

2. M6P/IGF-II receptor has recently been implicated in fetal development and
carcinogenesis. The mitogenic response through IGF-II binding to IGF-II receptor
may also be blocked by IGF-II ribozyme by decreasing IGF-II levels.

3. It is possible that the IGF-II receptor indirectly affects mitogenic responses ofthe
IGF-I receptor. Resulting in decreased availability ofIGF-II to the IGF-I receptor.

Similarly, reduction ofIGF-II levels may increase IGFBP expression, which in tum

binds IGF-II, resulting in decreased availability ofIGF-II to the IGF-I receptor.
Likewise,IGFBP proteinases may be downregulated in R-expressing cells, which
may result in increased IGFBPs,in turn binding IGF-II, resulting in decreased
availability ofIGF-II to the IGF-I receptor.
4. In the cell growth experiments, ribozyme expressing PC-3 cells showed growth
inhibition in both serum-Ifee medium and 2% FCS medium. Parental and vector

expressing PC-3 cells continued to grow in 2% FCS,but showed slower growth in
serum free medium. This may indicate that other factors in serum may also be

important for PC-3 cell growth. Since serum-deprivation is a stimuli for apoptosis,
ribozyme action and apoptosis through serum-deprivation both make contributions to
delaying cancer cell growth in these experiments. Further studies are thus required to
understand mechamisms by which ribozyme expressing cells undergo apoptosis.
E. Prostate cancer therapy

Prostate cancer represents a heterogeneous disease entity with varying degrees of
behavior, aggressiveness, patterns of metastasis, and response to therapy. Progressive
metastatic prostate cancer is associated with a formidable array of morbidity that
ultimately contributes to death ofthe patient. Androgen ablation remains the primary
systemic therapeutic modality for this disease, yet the intense delineation of

mechanisms involved in tumor cell metastasis has lead to new therapeutic strategies,
ranging from cytotoxic to cytostatic, including immunomodulators. Among those
strategies currently being studied are granulocyte-macrophage colony-stimulating

factor-transduced prostate cancer vaccines, inducers of apoptosis, antimetastatic
agents, angiogenesis inhibitors, radiation therapy (local and systemic), systemic
approaches targeted at prostate cancer morbidity and gene therapy. We must

acknowlege that cancer is a very complex disease, usually not due to one lesion, but
many lesions accumulated through the aging process. It is more like network
breakdown, causing chaos of cells. Accordingly, since treatment of cancer can not be
achieved by a single therapy, combined therapy usually prevails. With more
understanding of molecular mechanisms, gene therapy such as ribozymes may play a

role in cancer therapy, providing an additional promising modality.
F. Conclusion

In recent years, IGF-II has been shown to be an important factor for prostate
cancer cell growth. Thus,IGF-II provides a good target for gene manipulation. This

work presents the first comprehensive investigation of the role ofIGF-II in androgen-

independent prostate cancer cell growth using IGF-II ribozymes. It provides support
for the hypothesis that prostate cancer cell growth is regulated by IGF-II, and that
IGF-II is required for prostate cancer cell growth. In summary,ribozyme gene
therapy can be used to decrease IGF-II levels in prostate cancer cells. Since IGF-II

reduction decreases tumor growth and stimulates apoptosis, it represents a promising
therapeutic target to treat prostate cancer patients.
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